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General introduction 
Hepatitis C virus (HCV) infection is widely present throughout the world 
and approximately Ί 80 million people are infected with chronic hepatitis 
C virus The course of acute HCV infection is often subclinical and the 
majority (75%) of patients will develop chronic hepatitis C Chronic HCV 
causes hepatic inflammation which may lead to liver fibrosis and can 
result in a broad spectrum of disease outcomes Current treatment of 
chronic HCV consists of pegmterferon alfa in combination with nbavinn and 
results in a sustained virological response (SVR) of approximately 50% 
in genotype 1 and 4 and 80% in genotype 2 and 3 The introduction 
of this thesis focuses on the epidemiology of HCV in the Netherlands 
and the role of ribavirin in treatment 
Hepatitis C virus 
Chronic HCV causes hepatic inflammation which may lead to fibrosis. Cohort studies 
suggest that 20-30% of the patients will develop liver cirrhosis with all subsequent 
complications such as ascites, encephalopathy, variceal bleeding and hepatocellular 
carcinoma1. Figure 1 shows the natural history of hepatitis C. 













The genetic sequence of hepatitis C virus (HCV) was elucidated in 19892. HCV 
is an RNA virus that shows molecular similarities in genome organisation with 
the family of flaviviruses3. HCV primarily targets hepatocytes, however, infection 
and viral replication may occur in non-hepatic cells such as white blood cells4·5. 
HCV is primarily transmitted by exposure to infected blood. Factors most strongly 
associated with HCV infection are intravenous drug use, receipt of blood transfusion 









Six genotypes and multiple subtypes of HCV have been identified on basis of 
molecular relatedness. In the western world (United States and Western Europe) 
genotype la , l b are most common followed by genotype 2 and 3. The other 
genotypes are rare in these countries, but are common in other areas, such as 
Egypt (genotype 4), South-Africa (genotype 5) and Southeast Asia (genotype 6)9·10. 
Knowledge of the genotype is important because it has predictive value among 
other factors in terms of the response to antiviral therapy, with better responses 
associated with genotype 2 and 3 than with genotype1113. 
Epidemiology 
Global prevalence 
It is estimated that approximately 180 million people worldwide are infected with 
HCV6'14. Description of HCV global epidemiology relies heavily upon HCV seropreva-
lence studies that are typically done in selected populations, which can overestimate 
or underestimate the actual prevalence in the whole region. The prevalence of HCV 
infection varies greatly throughout the world. Areas with an estimated low HCV 
prevalence (<1%), include north-west Europe Canada and Australia. In Africa, 
South Asia and the East Mediterranean the reported prevalence is much higher. In 
the United States, for example, approximately 1.8% of the population tests positive 
for HCV antibodies615. The highest infection rates (15-20%) are found in Egypt, as a 
result of a nationwide antischistomosal vaccination programs, due to insufficient 
sterilisation of re-used injection material16. 
I he Netherlands 
In the Netherlands there have been only a few studies that investigated the preva-
lence of HCV in the general population17. In a large seroprevalence survey dating from 
1995, 0.08% of Dutch inhabitants tested positive for HCV-antibodies18. The main 
criticism was that the population of the study sample did not represent the Dutch 
population as those subpopulations with a probably higher prevalence (immigrants) 
were undersampled. As a corollary, the true prevalence in the Netherlands is likely 
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to be higher (0.1%-0.4%)19. There are a number of high risk populations with 
higher HCV prevalence compared to the general population; 1) i.v. drugs-users 
47-79%, 2) recipients of blood and blood products before 1990 0.17%, especially 
haemophiliacs 55%, 3) haemodialysis patients 2-3.5%20'21. The first generation 
immigrants, and individuals who were subjected to medical procedures abroad 
(prevalence depends on country of origin) and children born to HCV infected 
mothers (4-20% dependent on HIV status of the mother). Since 2000, another risk 
group has emerged. Approximately 15-20% of HIV-positive men who have sex with 
men were infected with HCV22. 
HCV treatment 
The principle aim of HCV treatment is to strive for permanent HCV eradication 
which is defined as a sustained virological response (SVR). The history of HCV 
treatment started in the eighties of the last century when researchers from the NIH 
discovered that interferon-alfa appeared to be effective in a subset of HCV 
patients. Upon scrutiny it emerged that the succes rates of this treatment was 
limited and that only 16-20% achieved SVR23·24. 
Due to the low efficacy of solo interferon-alfa treatment, the search for additional 
agents continued. Supplementation of ribavirin, an old antiviral agent, to interferon-
alfa monotherapy indeed doubled the response rates to 35-40%25'26. Further 
improvements were made and a new formulation of interferon-alfa with the 
addition of polyethylene glycol (peginterferon) was invented. These developments 
have led to the current standard of treatment with peginterferon-alfa in combination 
with weight-based ribavirin. This results in SVR rates up to 54-56% in genotype 1 or 4 
and 70-80% in genotype 2 or 31113. 
Side-effects are common during antiviral therapy and are often a reason for 
dose adjustment or discontinuation. Typical peginterferon-alfa side effects include 
flu-like symptoms, haematological bone-marrow depression, dermatitis and mood 
disorders. 
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The major problem with ribavirin is the dose-limiting haemolytic anaemia, which is 
mainly caused by the extensive phosphorylation of ribavirin m the erythrocyte27 
Ribavirm-mduced anaemia is typically managed by dose reduction or discontinua­
tion of the drug Furthermore erythropoietin substitution improves haemoglobin 
levels, which allows for dosage maintenance and improve quality of life during 
treatment2 8 3 1 
Ribavirin 
In combination therapy, ribavirin dramatically improved the success of therapy25 26 
The recommended daily dose of ribavirin depends on body-weight and genotype 
1 1 1 3 The optimal dose of ribavirin remains uncertain and a few studies suggest a 
correlation between higher plasma ribavirin concentrations and higher response 
rates32 36 However, administering higher ribavirin doses must be balanced against 
potential increases m drug-related haemolysis In this thesis we want to explore 
the relationship between ribavirin dose, its pharmacokinetics and treatment 
outcomes Therefore, the focus will be on ribavirin m the next underlying sections 
The role of ribavirin 
In 1970 a triazole nucleoside, l-ß-D-ribofuranosyl-l,2,4-triazole-3-carboxamide 
was synthesized by scientists at ICN Pharmaceuticals' Nucleic Acid Research 
Institute3738 This agent has a remarkable broad spectrum of antiviral activity in 
both m vitro and in vivo systems In vitro, ribavirin exhibits antiviral activity against 
various DNA and RNA viruses, such as Herpes, adenoviruses and influenza A/B, 
Coxsackie, pohovirus (type 1 and 2) and rotaviruses, respectively3942 In vivo, m 
various clinical trials patients with acute hepatitis A were treated with different 
ribavirin dosages and showed positive antiviral effect Ribavirin did not show 
efficacy against chronic hepatitis B39 
In view of the antiviral properties, ribavirin was investigated as monotherapy for HCV 
The clinical efficacy was disappointing as ribavirin monotherapy did not cure HCV43 
Pharmacokinetics and mechanism of action of 
ribavirin 
Ribavirin is absorbed in the gastrointestinal tract and is transported across the cell 
membrane by an es-type equilibrative nucleoside transporter4"'45. Ribavirin is 
rapidly and extensively absorbed following oral administration. The bioavailability 
is reported to be 40-50%45 47. The half-life of ribavirin is long and is clearly dependent 
on the distribution and clearance. Thereby steady state is slowly reached (4-5 ti/2 
is needed to reach >90% of steady state concentration). Elimination of ribavirin 
occurs via two metabolic pathways: 1) reversible phosphorylation to mono-, di-, 
and triphosphate metabolites and 2) degradation involving deribosylation and 
amide hydrolysis to yield a triazole carboxime metabolite48·49. 
Ribavirin plasma concentration 
Ribavirin is currently administered to HCV patients in a weight-based manner. 
The wide interindividual variability of ribavirin plasma concentrations has led to a 
series of studies that examined the association between plasma concentrations, 
toxicity and clinical outcome of treatment. Therapeutic drug monitoring (TDM) may 
be helpful in balancing harm versus benefit. Several studies report that plasma 
concentration at week 4 is a predictor of SVR and a more recent paper showed that 
SVR may be predicted on basis of day 1 ribavirin plasma concentration.35'50·51. In both 
HCV/HIV infected and HCV mono-infected patients, higher plasma concentration at 
3 and 6 months were seen in responders compared to non-responders52-53. These 
results have been contradicted by other studies, probably due to small sample size, 
retrospective design, sampling error with variations in time of sampling ribavirin 
plasma concentration and sampling media (plasma vs. serum)51'54·55. 
To date, no report has been conclusive about the benefit of TDM of ribavirin 
concentration in clinical practice. 
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Mode of action 
The mechanism by which ribavirin acts is incompletely understood, and a number 
of hypothetical mechanisms are proposed to explain the anti-HCV efficacy56-58. 
These proposed mechanisms are based on in vi tro and vivo data and include 1) di-
rect inhibit ion of RNA-dependent RNA polymerase (RdRp), a key enzyme in viral 
replicative machinery 2) inhibit ion of host inosine monophosphate dehydrogenase 
(IMPDH), which reduce viral replication; 3) enhancement of cell-mediated host im-
munity against virus; and 4) act as a RNA mutagen, that would lead to "error catas-
trophe," that is disorganization of the mutant distr ibution of the quasipecies and 
the generation of nonviable viral populations in vitro59·60 (figure 2). The last mech-
anism investigated in vivo showed that ribavirin does not act as a RNA mutagen61, 
so the mechanism of ribavirin remains as elusive as ever. 





l)Direct inhibition of viral replication; 2) Inhibition of the enzyme inosine monophosphate 
dehydrogenase (IMPDH); 3) Immunomodulation; 4) mutagenesis. 
GIP, guanosine triphosphate, IMP, inosine monophosphate, RdRp, RNA-dependent RNA 
polymerase, RMP, RDP, RTP, ribavirin mono-, di- and triphosphate. 
Reproduced with permission from the author [62], 
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Future role of ribavirin 
Further improvement of HCV treatment for difficult-to-treat genotypes 1 and 4, is 
considered to be the greatest challenge Several studies have investigated the 
concept of higher ribavirin dosage in difficult-to-treat HCV genotype 1 in order to 
obtain higher SVR rates Two studies suggests that 1600 mg/day further increases 
SVR rates6364 Furthermore, a small pilot study was performed m 10 genotype 1 
patients with a mean ribavirin dose of 2540 mg/day (range 1600-3600 mg/day) 
This resulted in 90% SVR All patients experienced anemia, which was treated with 
concomitant epoetin beta and blood transfusion65 
The future of HCV treatment involves the use of Specifically Targeted Antiviral 
Therapy against HCV (STAT-C) Many protease and polymerase inhibitors have 
already been developed and evaluated in clinical trials for this purpose Two 
protease inhibitors, Telaprevir (VX950) and Boceprevir (SCH503034), have recently 
entered phase III clinical trials and initial results are encouraging A number of 
studies have demonstrated that STAT-C monotherapy is not effective and that 
addition of pegmterferon-alfa and ribavirin is crucial Specifically ribavirin appears 
to be an essential component and its addition to STAT-C drugs improved SVR rates 
significantly6667 
Outline of this thesis 
The mam aim of this thesis was to evaluate whether and how current HCV antiviral 
treatment can be optimized with a focus on the role of ribavirin 
In chapter 1, the introduction, we describe HCV infection, treatment and the role 
of ribavirin m combination therapy 
Chapter 2, describes the prevalence of HCV m the Dutch population, because little 
is known about the actual prevalence of HCV infection in the Netherlands Further-
more in this chapter, we studied the current clinical care for HCV patients provided 
by Dutch physicians, and we wanted to identify areas for future improvement of 
the current treatment 
is 
O due' 
In chapter 3, we describe two meta-analyses. In the first meta-analysis, we pooled 8 
studies to determine the optimal length of treatment in patients with HCV genotype 
2 and 3. Several randomised clinical trials (RCTs) investigated whether shorter treat-
ment duration is equally effective as standard length of therapy in achieving sustained 
viral response (SVR). This is important because side effects are common during 
HCV treatment and economic consideration favour shorter treatment duration. 
The second meta-analysis was conducted in order to determine whether a higher 
ribavirin dosage is more effective than standard ribavirin dosages in HCV combination 
therapy. Ribavirin is an important component in HCV treatment and several RCTs 
have been performed studying differences in SVR rates with higher dosage regimens 
of ribavirin. 
Chapter 4 includes two studies that describe the plasma ribavirin concentrations 
in HCV treatment. First, we investigate plasma ribavirin concentrations and the 
inter- and intrapatient variability in clinical practice. Secondly, we show preliminary 
results of the ribavirin plasma concentration collected during the VIRID study, 
which we are currently conducting68. The VIRID study is primarily designed to 
investigate the effect of higher ribavirin dosage in combination therapy on SVR in 
HCV genotype 1 and 4 patients68. In the sub-study, we investigate whether higher 
ribavirin dosage carries a different pharmacokinetic profile compared to standard 
dosing of ribavirin. 
The general discussion, chapter 5, summarizes the main findings. Finally, recommen-
dations for future research are presented. 
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Chronic hepatitis C virus (HCV) is transmitted by blood blood contact 
and this leads to high HCV prevalence in risk populations such as 
haemophilia patients and intravenous drug users The prevalence in 
the general Dutch population is unknown, although it appears to be 
very low in screened blood donors (0 0169%) 
The objective of this study is to estimate the prevalence of HCV in 
a general population sample living in an urbanised region in the 
Netherlands 
We randomly selected 2,200 EDTA blood samples that had been 
submitted for analysis of biochemical parameters to a regional servicing 
laboratory for general practitioners (SHO, Arnhem/Nijmegen, the 
Netherlands) HCV antibody testing was performed using a three-step 
approach For initial screening, an enzyme immunoassay (Bioelisa HCV 
4 0, Biokit, Spam) was used Positive samples were subjected to a 
second, microparticle enzyme linked immunoassay (AxSYM HCV version 
3 0, Abbott laboratories, L , USA) Genotypes were determined by Line 
Probe Assay A total of four persons (two females, two males) (0 296) 
tested positive for HCV antibodies The average CD / cut off ratio of the 
screening assay was 2 9 (range 1 0 to 7 3) and serological findings were 
confirmed using a specific second immunoassay HCV RNA (genotype 
1 b) was found in the sera of two persons 
The HCV prevalence in our sample of the Dutch population was 0 2% 
which accords with earlier estimates from prevalence studies in the 
Netherlands 
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Background 
Hepatitis C virus (HCV) is mainly transmitted through contact with blood and blood 
products. The majority of HCV-seropositive individuals will have persistent viraemia. 
More than half of all patients will develop chronic hepatitis, and in 20% infection will 
lead to cirrhosis with all the subsequent complications, such as ascites, encephal-
opathy, variceal bleeding and hepatocellular carcinoma1. 
Chronic HCV infection often runs an asymptomatic course and only 25 to 30% of in-
fected persons seek medical attention for symptoms attributable to HCV infection.2 
Early detection is of key importance in order to prevent complications of HCV-related 
liver disease. The WHO estimates that 3% of the world's population is HCV-infected 
and in the USA it is a leading cause of liver transplantations3·4. 
It is thus a significant clinical problem. However, there is wide variation in HCV prev-
alence in different parts of the world. For example, the prevalence in Scandinavia is 
less than 0.5%, whereas the prevalence in Egypt is over 20%5. In the UK, the number 
of new HCV diagnoses rose from 2,116 in 1996 to 7,580 in 2005. Hospital admissions, 
transplants, and deaths related to HCV increased, and deaths from end-stage liver 
disease rose from 76 in 1997-8 to 216 in 2004-5. 
These results suggest that the number of people at risk for HCV-associated morbidity 
or mortality will double over the next decade in the UK6·7. In the Netherlands there 
have been only a few studies that focus on the prevalence of HCV. These studies 
were generally limited to high-risk populations, such as intravenous drug users and 
haemophilia patients. Some 54% of Dutch haemophilia patients are HCV carriers, 
and up to 74% of iv drug users are infected8. 
In 2000, two nationwide prospective surveys among 2,281 and 2,286 dialysis patients 
resulted in an HCV prevalence of 2.9 and 3.4%, respectively9. The prevalence m the 
general population is estimated to be much lower (0.1 to 0.4%). However, this is a 
crude estimation based on extrapolation of the prevalence among selected high- and 
low-risk groups1011 Thus, the actual prevalence in the population at large is unknown, 
hence the need for population-based serological studies. These data are desirable 
because they allow medical professionals and policymakers to develop and evaluate 
efforts with respect to treatment and prevention. Therefore, the aim of this study 
is to determine the prevalence of HCV infection and the distribution of genotypes 
in the general Dutch population in urbanized regions of the East-Netherlands. 
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Materials and Methods 
I 'jtion's and sottmq 
Data for the present study were collected prospectively from 2,200 persons visiting 
general practices in the urbanized regions of Arnhem/Nijmegen in June 2006. Patients 
had been referred to a servicing laboratory (SHO) by the general practitioner for 
analysis of biochemical parameters. After determination of the desired parameters, 
the remaining blood samples were stored at 4°C until transport to the laboratory of 
Radboud University Medical Centre in Nijmegen. All aspects of the protocol were 
reviewed and approved by the local medical ethical committee (CMO) Arnhem/ 
Nijmegen, the Netherlands. 
_ lì ' C • ~ ^ O l C 
Immediately after arrival to the laboratory, samples were centrifuged. Sera were 
then stored in aliquots at -80°C. 
Arilib'yj1) lesliny 
HCV antibody testing was performed using a three-step approach. For initial 
screening, an enzyme immunoassay (bioelisa HCV 4.0, Biokit, Barcelona, Spain) 
was used. Microtitre plates are coated with recombinant HCV antigens including 
core, NS3, NS4 and NS5. The cut-off value was determined by multiplying the mean 
optical density (OD) value of the low positive control by 0.9. Ratios of sample OD 
value and cut-off value of >1 were considered positive. Positive samples were 
further tested by a second, commonly used microparticle enzyme-linked immuno-
assay (AxSYM HCV version 3.0, Abbott Laboratories, IL, USA), because the Biokit 
assay is considered as sensitive as the AxSYM but somewhat less specific according 
to the information supplied by the manufacturer. Positive results in the AxSYM 
assay were then further tested using a recombinant immunoblot assay (INNO-LIA 
HCVTM Score, Innogenetics NV, Gent, Belgium). 
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Antibody positive samples were tested for the presence of viral RNA and the 
HCV genotype. For isolation of HCV RNA the COBAS® AmpliPrep (Roche Molecular 
Systems, Branchburg, USA) was used according to the manufacturer's instructions. 
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Isolated HCV RNA was detected using the COBAS® TaqMan® HCV Analyzer real time 
PCR. Results are given in lU/ml. The detection range lies between 15 and 7 χ 107 ID/ 
ml. Hepatitis C genotype was determined using a Line Probe Assay LiPA, based on 
sequence variations found in the 5' untranslated region of the different HCV geno­
types (VERSANT HCV Genotype Assay, Bayer Healthcare LLC, USA) as described 
before12. All assays were performed according to the manufacturer's instructions. 
SMII li dl rjnaly.i'. 
Quantitative results are reported as the mean ± standard deviation, and qualitative 
results are given as percentages. For comparison of proportions between groups, 
x2, Fisher tests and independent T-tests were used. If a ρ value was below 0.05, the 
difference between proportions was considered statistically significant. 
Results 
In total 2,200 subjects were tested on HCV antibodies. This group consisted of 1,254 
(57%) females and 928 (42.2%) males with a mean age of 60.4 years (SD = 16.6). 
Demographical data on 18 patients were lacking, but they tested HCV negative using 
our testing strategy. Figure 1 shows the strategy we followed to determine the HCV 
positivity. 
In the initial screening using the Biokit assay, 16 out of 2,200 (0.7%) subjects had a 
positive test result with OD values varying from 1.016 to 8.466. Results from two 
additional samples were ambiguous with values of 0.919 and 0.949. There were no 
significant differences with respect to age and gender of subjects between those 
with a positive and those with a negative ELISA (p=ns) (table 1). 
These 16 positive and two ambiguous samples were subjected to further testing 
using an AxSYM assay. This established the presence of HCV antibodies in seven 
out of 16 positive samples (OD values of 37.36 to 82.82). Next we performed an 
immunoblot assay to confirm the HCV infection and were able to confirm the 
presence of specific anti-HCV antibodies in these four samples (two males, two 
females). Thus, the HCV prevalence in this sample can be estimated at 0.2%. 
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Figure 1 Flowchart of straloyy to determine hep ililis C virus (HCV) posilivily 
Bioelisa HCV4 0, Biokit 
AxSYM HCV version 3 0 
Immunoblot Assay 
2,200 random selected blood 
samples 
16 positive, 2 ambiguous for HCV 
antibodies 
7 positive HCV antibodies 
> 
4 positive HC V antibodies 
2,182 negative for 
HCV antibodies 
11 negative for 
HCV antibodies 
3 negative for HCV 
antibodies 





HCV test 1 
Negative Positive 
(n=2,166) (n=16) 
60 4(16 6) 614(17) 
1,244 (57 1) 10 (0 8) 
922(42 3) 6(0 6) 
HCV test 2 
Negative Positive 
(n=2,178) (n=4) 
60 4(16 6) 60 0(16 1) 
1,252 (57 5) 2 (50) 
926 (42 5) 2 (50) 
*= no age information about 7 subjects, **-no gender information about 11 subjects 
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Lastly, we searched for HCV RNA in these samples and detected viral RNA in two 
out of four samples. Both samples contained genotype l b . 
In order to test the robustness of our findings, we designed a novel study using our 
cohort and the dataset of an earlier study as a replication cohort1 5 1 6 We detected 
a positivity rate of 4/2,200 while the other study found 6/7,373 positive1516. Next we 
calculated whether both datasets were statistically different. Using Fisher's exact test 
we found that they were not (p=0.2). Subsequently we combined the datasets which 
yield a much larger cohort of 9,573, containing ten HCV-positive patients. The new 
prevalence was 0.10%, with a calculated 95% confidence interval of 0.039 to 0.17%. 
Discussion 
We performed a cross-sectional study to assess the epidemiology of HCV infection 
and we were able to estimate the prevalence at 0.2% among the general population 
residing in the eastern part of the Netherlands. Most of the previous research in 
this field had been conducted in high-risk groups or in blood donors, which may 
over- or under-estimate the actual burden of HCV infection in the general population. 
How do these data compare with other studies in this field? 
The prevalence (0.2%) from this study is appreciably higher compared with healthy 
blood donors from the Netherlands. In 2001 approximately 0.0169% of new blood 
donors tested positive for HCV antibodies13. 
In comparison, the HCV prevalence rates among healthy blood donors range 
from 0.01 to 0.02% in the North-Western Europe, to 1 to 5% in Southern Europe14. 
While interpreting these results, it is important to realize that blood donors are a 
self-selected group of individuals who have lower rates of blood-borne infections 
compared with the general population. Many of the people with risk factors for 
infection due to HCV (parenteral drug addiction, previous history of hepatitis) are 
rejected as blood donors. Therefore, these prevalence rates probably underestimate 
the actual HCV carrier rate. 
To this end, in another Dutch study a nationwide call was sent out for volunteers to 
give sera. The general public was invited by postal request to donate blood samples 
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and the study went to great lengths to obtain a well-balanced age mix among the 
different geographic regions This study measured HCV antibodies among a sample 
of 7,373 volunteers and found that only six tested anti-HCV positive (0 08%)1516 
When we combined this dataset with our own data, the cohort now encompasses 
a sample of 9,573 patients and yields an HCV prevalence of 0 10% (95% CI 0 039 
to 0 17%) 
In our study, we analysed sera obtained from subjects who underwent blood analysis 
for various reasons requested by their general practitioners m the Arnhem/Nijmegen 
region This is a potential source of bias as we selected subjects who had a reason 
to go to their general practitioner and have blood taken However, blood analysis 
m primary care is a common procedure, often used for the exclusion of severe 
disorders or for the reassurance of the physician or the patient that there is no 
severe pathology of underlying symptoms As the incidence of serious diseases 
is low m the general practice population, it can be assumed that the observed 
prevalence of HCV is representative for the general population1719 
This study was performed m the eastern part of the Netherlands, which is an urban 
region with a smaller immigration population of 13 7% in Gelderland compared 
with 25 1% m the Utrecht/North-Holland/South-Holland regions, which may affect 
the findings20 
Anti-HCV testing is performed m different settings, including hospitals, other 
healthcare facilities and also for screening purposes Therefore the most desirable 
HCV screening is the test that has a very high specificity 
Consequently, this might lead to a lower sensitivity Therefore in line with recom-
mendations published elsewhere we decided to perform a second confirmatory 
ELISA m the positive samples21 
Indeed, this was beneficial as it led to exclusion of the suspicion of HCV infection m 
nine of the 16 samples (56%) It is possible that a larger sample would have led to 
different results but in view of the abovementioned studies it is probable that 
the real HCV prevalence m the Netherlands is well below 0 5%, though we cannot 
exclude that there is a wide region-region variation Other possible limitations 
include the absence of detailed information on whether these patients were aware 
of their infection and whether they had had treatment In addition, HCV RNA could 
not be detected m two of the four subjects with HCV-positive antibodies This 
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can be explained by a decline in viral load during storage of the tubes or because 
the two subjects had cleared the HCV. It is known that around 20% of patients 
spontaneously clear HCV". 
The genotypes detected in our sample (lb) is the most common genotype in the 
Netherlands. A recent study performed by de Vries et al. showed that genotype 1 
is found in approximately 50% of HCV patients in the Netherlands22. 
How does this prevalence compare with other countries? In the USA, the prevalence 
of HCV infection is estimated at 1.6%3. Various studies performed throughout Europe 
on the prevalence of HCV in general population indicate prevalences from 0.63% in 
Germany, 0.9% in Belgium to 1.2% in France2325. In Southern Europe the prevalence 
varies from 1.6% in Spain to 4.8 to 26.0% in Italy2627. The HCV prevalence is higher 
in Southern Italy compared with Northern Italy. The large variation is most probably 
due to differences in the quality of the healthcare system. In the recent past, 
healthcare facilities in Southern Italy made extensive use of glass syringes, and/or 
non-sterile syringe use facilitating nosocomial HCV transmission28. Our results 
show lower HCV infection rates in the Dutch 
population compared with those found in other countries in Europe. Further, this 
accords with a North-South gradient in HCV prevalence in Europe. 
Conclusion 
The current study provides information on HCV prevalence in the general population. 
We found an HCV prevalence of 0.2% in the general population. Combining our data 
with other observations provides a point estimate of 0.10%, with a 95% confidence 
interval of 0.039 to 0.17%, which is clearly lower than in other European countries. 
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Recently, the Dutch Association of Gastroenterology and Hepatology 
issued new guidelines for the treatment of chronic hepatitis C virus 
(HCV) These guidelines reflect the current standard of care Before 
these guidelines were published and implemented we (1) studied 
the current clinical care of HCV patients among Dutch physicians, 
and (2) identified areas for future refinement in the current treatment 
We conducted a non targeted survey among Dutch medical specialists 
in Gastroenterology, Hepatology and Internal Medicine who actively treat 
HCV patients The questionnaire contained items about facility, duration 
and dosing of treatment, and side effect management using clinical 
vignettes followed by short questions 
We received 49 questionnaires from treating HCV specialists The 
majority (65%) of respondents treat HCV patients during regular out 
patient clinics, while 35% treat these patients in a separate setting 
dedicated to the care of HCV patients The majority of physicians 
follow the stipulated dosage regimens of pegylated interferon (88%) 
and ribavirin (83%) A minority (13%) exceed the advised dosage of 
ribavirin Side effects such as neutropenia are mostly managed by 
decreasing the interferon dosage (42%) Some 35% of physicians 
reduce ribavirin if haemoglobin levels drop below 5 4 mmol/l, and 41 % 
initiate erythropoietin treatment 
Dutch clinical practice reflects the recently issued HCV guidelines An 
important area of refinement in treatment of HCV is the management of 
side effects 
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Introduction 
Chronic hepatitis C virus (HCV) is one of the most common chronic viral infections 
throughout the world and is a primary cause of cirrhosis and hepatocellulair carci-
noma1. Treatment of HCV has improved steadily during the last decade, and with 
the current standard of care, that is treatment with pegylated interferon and 
ribavirin, sustained virological response (SVR) rates of 50% among genotypes 1 and 
4, and 80% among genotypes 2 and 3 have become possible2·3. 
The selection of patients who benefit most from therapy and close monitoring of 
hepatitis C treatment are crucial components of hepatitis C therapy. These aspects, 
and the wealth of clinical data that stem from a large number of clinical trials, have 
led to the formulation of international guidelines4'5. Given the intensive treatment 
schedule with side effects, long treatment duration and high costs of therapy, it 
is important that physicians follow evidence-based guidelines in order to improve 
patient outcome and give the best care available4-5. 
Recently, the first Dutch national guideline 'Treatment of chronic hepatitis C virus 
infection' was formulated by the Dutch Association of Gastroenterologists and 
Hepatologists6. This guideline for HCV mono-infection provides recommendations 
on diagnostic evaluation, choice of the (initial) antiviral treatment and the follow-
up during and after antiviral therapy (table 1, figure I)6. 
Although clinical trials have demonstrated the benefit of combination therapy in 
patients with chronic HCV, how this translates into actual benefit in practice that 
can be attributed to knowledge of and adherence to guidelines is unclear. The primary 
objective of this study was to evaluate current clinical practice among Dutch physi-
cians who actively see and treat chronic HCV patients. A secondary objective was 
to identify dimensions of the guideline that potentially benefit from refinement or 
adjustment. 
Methods 
We conducted a non-targeted survey among Dutch medical specialists in Gastroen-
terology, Hepatology and Internal Medicine. These physicians were selected from 
membership directories of the Dutch Society of Hepatology and the Infectious 
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Figure 1 Flowchart for the Irpitmpnt ot patients with chronic hepatitis C mono inlet lion according 
to the recently issued Dutch guideline 6 
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Table 1. Mam recommendations for trealmeni and management ol chronic HCV patients6 
Dutch guideline % followed 
guideline* 
Dosage 
HCV genotype 1 & 4 
HCV genotype 2 & 3 
Peg-IFN a-2a 180 μg/wk + weight based RBV/day or 
Peg-IFN a-2b 1.5 μg/kg/wk + weight based RBV/day 
Peg-IFN a-2a 180 μg/wk + 800 mg RBV/day or 




HCV genotype 1 & 4 
HCV genotype 2 & 3 
48 weeks of treatment 
Exception: <600,000 viral load (lU/ml) at baseline with RVR 24 weeks of treatment 
24 weeks of treatment 







ANC < 0 75xl07l: PEG-IFN dose to 75% 
ANC < 0 375χ109/Ι· PEG-IFN dose to 50% 
Hb < 5 0 mmol/l give erythropoietin 
Hb < 4.0 mmol/l, decrease dose RBV to 800 mg/day and give erythropoietin and blood transfusion 
35% 
25% 
HCV = Hepatitis C Virus, Peg-IFN = peginterferon, RBV = ribavirin, RVR = rapid viral response, ANC = absolute neutrophil count; Hb = Hemoglobin. ·% physicians who treat 
according to the Dutch guideline 
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Disease Society of the Netherlands and were sent a postal questionnaire; physicians 
who actively treated HCV patients were asked to return the questionnaire. The 
postal questionnaire included four important issues: the first part discussed the 
setting of the treatment: a regular outpatient clinic or a separate setting dedicated 
to the care of HCV patients. The second and third part of the survey focused on 
peginterferon and ribavirin treatment for HCV patients: detailed questions using 
clinical vignettes were included about the treatment duration and dosage of the 
drugs, respectively. The last part focused on side effects, their consequences, and 
management in terms of dose reduction or treatment of possible side effects. The 
questionnaire consisted of clinical vignettes followed by a mix of short multiple-choice 
and open-ended questions. For example: 'A male HCV genotype 1 patient starts the 
combination therapy (peginterferon 180 μg/ week and weight-based ribavirin 
daily); at the start of the treatment the haemoglobin (Hb) level is 8.0 mmol/l. 
After eight weeks the patient's Hb has decreased to 5.4 mmol/l. What to do? 
1) Continue combination therapy. 2) Stop ribavirin (whether or not temporarily). 
3) Reduce ribavirin to 50%. 4) Give erythropoietin. 5) Give blood transfusion.' Data 
from returned questionnaires were entered into a Microsoft Access database, and 
frequency tables were provided by SPSS 14.0 for Windows. 
Results 
A total of 64 questionnaires were received. Although explicitly indicated, 15 respond­
ing specialists were not actively treating HCV patients and were excluded from further 
analysis. Forty-nine questionnaires were suitable for analysis. 
The majority (65%) of respondents treat HCV patients during regular outpatient 
clinics, while 35% treat patients in a separate setting dedicated to the care of HCV 
patients. 
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Week 12 and 24 measurements of viral load are important to judge treatment 
outcome. When asked, 67% of physicians would treat HCV genotype 1 patients 
with a detectable HCV viral load at week 12 and an undetectable HCV viral load at 
24 weeks for a total of 48 weeks (table 1), while 13 of the 49 respondents (27%) 
choose longer treatment (72 weeks). This is an area of controversy since the 
guideline indicates 48 weeks, but recent evidence suggests that prolonged 
treatment up to 72 weeks is beneficial in these cases7·8. 
The guideline recommends treating HCV genotype 3 patients for 24 weeks. Some 
70% of respondents treat HCV genotype 3 patients with significant cirrhosis for 24 
weeks, while a minority (22%) will treat for 48 weeks. For HCV genotype 3 patients 
who had a negative viral load at week 4, the guideline recommends treating for 12 
to 16 weeks. Thirty-seven percent of the respondents would treat for this period. 
The remainder choose a longer treatment duration than currently advised in the 
guideline. 
Respondents were also divided on treatment duration of genotype 1 patients with 
low viraemia (<600,000 Ill/ml) at the start of treatment, and a negative viral load 
at week 4. While following the guideline, some 55% would treat for 24 weeks, and 
45% would treat for 48 weeks. 
^ ILJ inn 
The recommended dosage of ribavirin for HCV genotype 1 patients is weight-based. 
Indeed, the majority of physicians treat an HCV genotype 1 patient with a weight of 
104 kg with ribavirin on a weight-based schedule (83%). A minority (13%) consistently 
exceeds this dosage. 
' c i nioi1orGn 
The vignette on the peginterferon dosage in an HCV genotype 1 patient weighing 150 
kg shows that 88% of the physicians administer the dosage exactly as stated in the 
guideline. Thus, peginterferon-a-2a, 180 μg/week, or weight-based peginterferon-
alfa-2b, 1.5 μg/week. The remainder choose a higher dosage than currently advised 
in the guideline. 
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Sido "foct manaqcmunt 
Neutropenia is a common event in HCV combination therapy and is usually attributed 
to the peginterferon component. Upon managing a patient with profound neutro­
penia (0.8 χ 109/1), 35% would continue current treatment, 42% would reduce 
(halve) the prescribed dosage of peginterferon, and 15% stop peginterferon (figure 2). 
Anaemia is caused by ribavirin-induced haemolysis, and if asked to decide for a 
patient with haemoglobin <5.4 mmol, the majority of physicians (41%) would 
initiate erythropoietin treatment, while 35% of physicians would reduce the 
ribavirin. Twenty-five percent continue both pegylated interferon and ribavirin 
unchanged ( figure 3). 
Discussion 
Our survey shows that most physicians treat patients with HCV in clinical practice 
according to this recently issued HCV guideline. 
Still there are some areas of controversy. Almost half of the physicians treat HCV 
genotype 1 and 3 patients with RVR longer than currently needed. In terms of 
financial aspects, occurrence of severe side effects and convenience for patients, 
shorter treatment duration with retained efficacy is desirable. 
Some 13% of the physicians use higher ribavirin dosages than currently advised. 
Some studies show that a higher starting dose of ribavirin is associated with a lower 
relapse rate and higher rate of SVR911. High-dose ribavirin is also associated with 
more frequent and serious side effects such as anaemia, which require erythropoietin 
in many cases911. More studies are necessary to judge whether the benefits of a 
higher ribavirin dosage needed to achieve SVR outweigh the disadvantages of the 
side effects12. Management of side effects has low evidential value and the current 
literature is mostly based on expert opinion. When a side effect, e.g. neutropenia 
or anaemia, occurs peginterferon and ribavirin are often reduced or stopped too 
soon,13 and this may hamper the achievement of SVR. On the other hand, if treatment 
of anaemia by erythropoietin is initiated too early, it leads to unnecessary 
expenses914. Supporting evidence in order to issue guidelines is clearly needed. 
Along the same line, neutropenia due to peginterferon can be controlled by 
granulocyte colony stimulating factor, but it is unclear which cut-off point should 
be used for initiating therapy. 
Epidemiology and current rimirai pradice 
This study has some limitations. We did not ask for respondents' demographics, 
professional background and/or hospital setting. It is unclear whether our findings 
are generalisable to all Dutch medical specialists in Gastroenterology, Hepatology 
and Internal Medicine. Altogether, data from our survey indicate that Dutch physi­
cians treat their HCV patients as described in the recently issued HCV treatment 
guideline. There is a paucity of data that enables evidence-based management of 
side effects during HCV therapy. 
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Current guidelines recommend a duration of 24 weeks of treatment 
with pegylated interferon and ribavirin for patients infected with chronic 
hepatitis C virus (HCV) genotypes 2 and 3 Several trials investigated 
whether shorter treatment duration is equally effective in achieving 
sustained virological response (SVR) 
Our aim was to determine the optimal length of treatment in patients 
with HCV genotypes 2 and 3 
A systematic literature search was performed and identified eight 
randomized controlled trials (RCTs) Meta-analyses were carried out on 
SVR data from three studies randomized at baseline and five studies 
randomized at rapid virological response (RVR) to either 12-16 weeks 
or a 24-week course 
Pooled SVR data were higher in standard treatment in RCTs that 
randomized at baseline, with a relative risk (RR) of 0 88 (95% confidence 
interval [CI] 0 76-1 01) The pooled proportion of SVR rates of RCTs 
that randomized at RVR were similar in the short treatment group (82%) 
as in the standard treatment (83%), with the pooled effect given by a 
RR of 1 00 (95% CI 0 92-1 09) 
A shorter course (12-16 weeks) of combination therapy does not 
impair efficacy compared with a 24-week course in HCV genotypes 2 
and 3 patients who achieve an RVR HCV patients without RVR should 
consider 24 weeks of treatment 
Oplimizdlion ol current hepatitis C treatment Meta analybeb 
Introduction 
Chronic infection with hepatitis C virus (HCV) affects approximately 170-180 million 
patients worldwide and is one of the main causes of chronic liver disease and liver 
transplantation in the US and in Europe1. The current treatment guidelines for 
patients infected with HCV genotypes 2 and 3 is pegylated interferon-a2a in 
combination with 800 mg ribavirin or pegylated interferon-a2b in combination 
with weight-based ribavirin for 24 weeks2·3. Approximately 80% of patients achieve 
sustained virological response (SVR) with this regimen4. However, side effects 
are common and their frequency increases with the length of treatment. This and 
economic consideration favour shorter treatment duration5·6. A number of ongoing 
clinical trials have been trying to identify the optimal length of therapy, safety 
profiles and cost-effectiveness for the treatment of these patients, but have 
yielded discordant results7. 
The largest trial to date (the Accelerate trial) described significantly lower SVR rates 
with 16 weeks of therapy in comparison with 24 weeks, even in patients who 
achieved rapid virological response (RVR) after 4 weeks of therapy6. By contrast, 
other studies have demonstrated that therapeutic success of a treatment course 
of 12-16 weeks as compared with 24 weeks is similar in patients who achieve a 
RVRB"11. Although these trials document that abbreviated HCV therapy might serve 
as a viable option, it remains unclear whether this holds for all HCV genotype 2 or 
3 patients under all circumstances. It is paramount to obtain a better estimate of 
the treatment effect in order to judge which patients benefit from further treatment 
refinements. Pooling data from the individual trials in a formal meta-analysis greatly 
increases statistical power and enables us to address this issue. 
Recently, a meta-analysis compared standard and shorter treatment and concluded 
that 24 weeks should remain the standard treatment duration for HCV genotype 2, 
high viraemic HCV genotype 3, and patients without an RVR might achieve improved 
SVR rates with longer treatment than the recommended 24 weeks12. However, 
this meta-analysis aimed to analyse the effect of genotype (2 or 3) on SVR data. In 
addition, the authors performed a meta-analysis to establish which duration of 
treatment would serve well in genotypes 2 and 3. In the second meta-analysis, the 
authors did not include all current studies that were available, and study designs 
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and randomization points were different. For example, two trials randomized at 
RVR, whereas one trial randomized at baseline61011. Andriulli et al.13 pooled SVR 
data from a Norwegian and an Italian study14. The Norwegian study was a non-
randomized pilot study and the Italian study was randomized at baseline1314. 
The purpose of this study is to systematically analyse all randomized controlled trials 
(RCTs) that compare short (12-16 weeks) versus standard (24 weeks) duration in HCV 
genotypes 2 and 3, in order to assess the relative efficacy of each arm. 
Methods 
We followed the QUORUM guidelines for all steps reported in this meta-analysis15. 
[ iterdlure • edrc h 
A systematic literature search with predefined search terms was carried out in 
Medline (PubMed), Cochrane CENTRAL, Web of Science® and ClinicalTrials.gov for 
articles and abstracts published from 2000 until 31 October 2008. The keywords 'HCV 
or hepatitis C', 'ribavirin or Rebetol ® or Copegus®' and 'interferon or pegylated inter-
feron or Pegasys® or Pegintron®' were combined (Figure 1). Our search was limited 
to human adult randomized clinical trials that were published in English literature. 
Figure 1. Search Strategy 













Medline (Pubmed), Cochrane CENTRAL, Web of Science· and Clinical trials gov were searched HCV, hepatitis C virus 
Stucl\ idee lien 
We included prospective studies that evaluated standard pegylated interferon and 
ribavirin combination therapy in HCV genotypes 2 and 3 patients and compared 
short (12-16 weeks) with standard (24 weeks) treatment duration. We adopted the 
following inclusion criteria: manuscripts written in English, patients with HCV geno-
type 2 or 3, use of standard combination therapy similar in both arms, randomized 
Oplimizalion of ourronl liopatilib C Irujlrnunl Mcla-analyses 
double-blind trials, availability of SVR rates in both arms, and the report was pub­
lished in a book, journal, proceeding or indexed abstraction. 
Exclusion criteria were studies referring to patients with HIV coinfection, hepatitis 
Β virus coinfection, decompensated liver cirrhosis, hepatocellular carcinoma, 
haemophilia, and liver or renal transplantation. Studies that involved previously 
treated patients, nonresponders or relapsers were excluded. 
/a'dit, assessment 
The quality of the RCTs was assessed and scored using the Jadad scale, which 
considers three items: randomization (1 point if yes or 2 points if the method to 
generate the sequence of randomization was described and appropriate), double 
blinding (1 point if yes or 2 points if the method of double blinding was described 
and appropriate) and description of withdrawals and dropouts (1 point)16. Maximal 
scoring for the RCTs in this metaanalysis was 3 points. All studies were RCTs and 
open label. One study was double blind until 16 weeks of treatment6. All studies 
described their dropouts. It was not possible to assess quality of the abstracts because 
we did not have access to a peer-review; therefore, a secondary meta-analysis was 
carried out without the abstracts. 
Data abstraction 
Titles and abstracts of all retrieved records and subsequently full-text articles were 
examined independently by two investigators (SS and IW) to identify RCTs that 
satisfied the inclusion criteria. Discrepancies in selection were resolved by discussion 
between authors of this meta-analysis. All data from the selected studies were 
extracted using a standardized data collection form. The following characteristics 
were recorded: the first author's name, year of publication, study design, funding 
by pharmaceutical company, full text and population (gender, ethnicity, age, body 
mass index, fibrosis stage and HCV viral load). 
Data were separated and extracted for short and standard treatment regarding 
the following: number of participants, duration of treatment, dosages and type of 
pegylated interferon and ribavirin, RVR, end of treatment (EOT) and SVR. In case of 
missing variables, we contacted the authors of the individual studies to obtain 
additional data. 
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The primary outcome of interest in this meta-analysis was to explore SVR rates of 
the RCTs. SVR is defined as a negative result on a qualitative PCR assay for HCV RNA 
6 months after the EOT. Secondary end points included RVR, defined as a negative 
result on a qualitative PCR assay for HCV RNA 4 weeks after the start of treatment, 
and EOT, defined as a negative result on a qualitative PCR assay for HCV RNA after 
termination of treatment (short [12-16 weeks] versus standard [24 weeks]). The 
number needed to treat is calculated as 1 divided by the absolute risk reduction. 
i ' i ι' J, -
The effect of the two management strategies on SVR rates in HCV genotype 2 or 3 
patients was expressed as a pooled relative risk (RR) with a 95% confidence interval 
(CI). Outcomes were analysed on an intention-to- treat basis. All data were pooled 
using a random effect model. Funnel plots of individual study results were created 
by plotting the RRs against sample size to detect asymmetry in the distribution of 
trials. All statistical analyses were performed using Review Manager version 5.0.16 
for Windows (provided by the Cochrane Collaboration, Copenhagen, Denmark). The 
presence of a publication bias was assessed on the basis of a funnel plot for asym­
metry. For formal statistical testing, we used a regression asymmetry test to obtain 
the degree of funnel plot asymmetry as measured by the intercept from regression 
of standard normal deviates against precision, both after log transformation. 
Results 
ιί ί ' ' ci'-Λ V r Τ Γ 0 
Our search identified 8 potential RCTs representing a total of 2,786 HCV genotype 
2 or 3 patients. A total of five RCTs were published as full papers6·9-11·17 and the 
remaining three studies in abstract form 1 8 2 0 . The selection of articles is depicted 
in Figure 2. The trial by Mangia et al.8 did not meet the inclusion criteria in our 
meta-analysis, as stratification was different in randomization. Randomization in 
the variable duration group was not performed; patients with RVR were treated 
for 12 weeks and those without RVR were treated for 24 weeks8. 
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Figure 2. Selection of articles 
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8 
Included RCTs had two different study designs. We identified RCTs that randomized 
at baseline (entry) of the study6·9,17 and RCTs that randomized to short and standard 
treatment after achieving RVR10·11·18-20. 
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For homogeneity of effect measures across the included studies, we performed 
two separate meta-analyses for both randomization moments to reflect our primary 
end point, SVR. One study published only SVR rates in short versus standard therapy 
and was limited to HCV genotype 2 patients17. 
Characteristics of the eight studies and corresponding study populations are given 
in Tables 1 and 2. 
The standard duration of treatment was 24 weeks for all studies. By contrast, the 
definition of 'short duration' differed among trials: three trials defined short treat­
ment duration as 16 weeks6-11'17, one trial as 14 weeks10 and four trials as 12 weeks 
of treatment9 1 8"2 0, respectively. For the benefit of this study, we analysed these 
various shorter lengths collectively, which showed no difference in achieving SVR. 
Pegylated interferon-a2a6'911'16'18 of 180 μg/ week was given in five studies, two 
studies used pegylated interferon-a2b of 1.5 μg/kg/week10'12 and one study used 
interferon 3 MIU thrice weekly18. 
Ribavirin was administered daily at a dosage depending on body weight of 800-1,400 
mg daily in six trials1 0 ·1 1 1 7 - 2 0 and at a fixed dose of 800 mg daily in 2 trials 6'9. 
Meld analysis of Ô. R HÎP-, nWet ui' iJumizaton at b-acviir,e 
The sample size weighted pooled proportion of SVR in standard (24 weeks) treatment 
was 74% compared with 63% in short (12-16 weeks) treatment. Pooled RVR rates 
after randomization at baseline in standard treatment was 63% versus 64% in short 
treatment. For the standard duration groups, SVR rates among three RCTs ranged 
from 70% to 95%6'9'17, and the highest success rate was found in the study that was 
restricted to patients with HCV genotype 2 infection17. SVR rates among short (12-16 
weeks) duration trials ranged from 59% to 94%6'9'17. Two large trials with a total of 
1,851 patients favoured standard (24 weeks) treatment with a RR of 0.75 (95% CI 
0.65-0.86) and 0.88 (95% CI 0.82-0.95)6'9. A third trial studying 150 patients supports 
equal efficacy with an RR of 0.99 (95% CI 0.91-1.08)17. Pooling of the collective 
data, revealed that SVR rates were consistently higher in patients who received 24 
weeks of treatment with an RR of 0.88 (95% CI 0.76-1.01; Figure 3). None of the trials 
produced significantly different rates, whereas the test for funnel plot asymmetry 
was not significant (Figure 4). 
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Optimization of current hepatitis C treatment: Meta-analyses 
Figure 3. Forest plot of sustained virologica! response after short versus standard hepatitis C virus therapy 
of trials that randomized at baseline 
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Sustained virologica! response rates of trials were significantly higher in the standard treatment group. A 
relative risk of 0.88 (95% confidence interval [CIJ 0.76-1.01) shows a favour for standard treatment. 
Heterogeneity: t 2=0.01; χ2=14.37, degrees of f r e e d o m ^ (P=O.00O8);l2=86%. Test for overall effect: 
z=1.78(P=0.08). M-H, Mantel-Haenszel. 














I I I 
t u 
'üo r i f 3 
f i l 
0.1 0.2 0.5 10 
RR 
No originai trial produced significant different rates and the test for funnel plot asymmetry 
was non-significant. RR, relative risk 
We then searched for reasons why shorter treatment apparently fails to benefit 
these patients and focused on the EOT response. Sample-size-weighted pooled 
proportion of EOT in standard treatment was 89% versus 93% in short treatment. 
Short treatment had a comparable EOT with the standard treatment group, showing 
a pooled RR of 1.05 (95% CI 1.02-1.08). We found that a higher proportion of 




The failure to detect an advantage of shorter treatment duration was not the result 
of an imbalance in the percentages of patients achieving RVR, which was comparable 
in both groups with a pooled RR of 1.04 (95% CI 0.98-1.11). 
Subanalysis of only HCV genotype 2 or 3 patients in trials randomized at baseline 
showed an advantage of standard treatment with a pooled RR of 0.85 (95% CI 0.69-
1.05) for genotype 2 and 0.88 (95% CI 0.64- 1.19) for genotype 3 (Figures 5 and 6). 
Figure 5. Forest plot of sustained virological response of hepatitis C virus genotype 2 trials that 
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z=l.S4(P=0.12). CI, confidence interval; M-H, Mantel-Haensrel. 
Figure 6. Forest plot of sustained virological response of hepatitis C virus genotype 3 trials that 
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Heterogeneity: τ2=0.04; χ2=9.12, degrees of freedom=l (P=0.OO3);l2=89%. Test for overall effect: 
z=0.85(P=0.39). CI, confidence interval; M-H, Mantel-Haenszel. 
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Meta-analysis of SVR rates in patients with RVR at 4 weeks 
SVR rates ranging from 79% to 91% for the standard duration group was similar to that 
of the short duration treatment, which ranged from 81% to 90%, with a sample-size-
weighted pooled proportion of SVR of 83% in the standard treatment comparable 
with 82% in the short treatment group10·11·18"20. All studies randomized patients at 
RVR, and the majority favoured short therapy. RR ranged from 0.89 to 1.14 n.18"20. 
In odds with these findings, another study on 298 patients favoured standard 
treatment duration, with a RR of 0.89 (95% CI 0.81-0.98)10. Therefore, the pooled 
effect suggested that shorter treatment is not different in efficacy compared with 
standard treatment in genotype 2 or 3 patients who achieve RVR by 4 weeks (RR of 
1.00 [95% CI 0.92-1.09]; Figure 7). This pooled effect was not different (RR of 1.00 
[95% CI 0.89-1.12]) when it was analysed excluding the study that used conventional 
interferon in combination with ribavirin instead of pegylated interferon combination 
therapy18. 
Figure 7. Forest plot of sustained virological response after short versus standard hepatitis C virus therapy tri­
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Sustained virological response rates of trials showed equal treatment duration outcomes, with a relative risk of 
1.00 (95% confidence interval [CI] 0.92-1.09). Dalgard et al. [10] favours standard treatment with a relative risk 
of 0.89 (95% CI 0.81-0.98]. Heterogeneity: τ2=0.00; χ2=7.22, degrees of freedom=4 (P=0.12);l2=45%. Test for 
overall effect: 2=0.02(P=0.99). CI, confidence interval; M-H, Mantel-Haenszel. 
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Furthermore, pooling the SVR data of randomization at RVR Including only full-text 
papers showed no statistically significant difference on effect of short versus standard 
treatment (RR 0.94 [95% CI 0.83-1.06]; Figure 8)No original trial produced signifi­
cantly different rates, whereas the test for funnel plot asymmetry was non-significant 
(Figure 9). 
Figure 8. Forest plot of sustained virological response after short versus standard hepatitis C virus therapy 
trials that randomized at rapid virological response without abstracts 
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CI, confidence interval; M-H, Mantel-Haenszel. 













No original trial produced significant different rates, whereas the test for funnel plot 
asymmetry was non-significant. RR, relative risk 
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EOT rates obtained from three trials were comparable In the standard group versus 
the short group with ranges from 76% to 96% and 87% to 94% In standard versus 
short treatment, respectively. The sample-slze-weighted pooled proportion of 89% 
in standard treatment compared with 91% In short treatment101119. Short treatment 
did have a comparable EOT with the standard treatment group, showing a pooled 
RR of 1.03 (95% CI 0.97-1.09). The overall relapse rate in the short treatment group 
was 18% compared with 17% in the 24 weeks of therapy. 
Subanalysis of only HCV genotype 2 or 3 patients In trials randomized at RVR suggest 
no statistically significant difference In short versus standard treatment, with a 
pooled RR of 0.98 (95% CI 0.89-1.07) and 0.92 (95% CI 0.80-1.05), respectively 
(Figures 10 and 11). 
Figure 10. Forest plot of sustained virological response of hepatitis C virus genotype 2 of trials that 
randomized at rapid virological responso 
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Heterogeneity: τ2=0.00; χ2=0.16, degrees of freedom=l (P=0.69);l2=0%. Test for overall effect: z=0.50(P=0.61). 
CI, confidence interval; M-H, Mantel-Haenszel. 
Figure 1 1 . Forest plot of sustained virological response of hepatitis C virus genotype 3 trials that 
randomized at rapid virological response 
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CI, confidence interval; M-H, Mantel-Haenszei. 
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The number needed to treat m this group was 94, which means that 94 patients 
should be treated and would achieve RVR with standard 24 weeks of treatment m 
order to obtain one more patient achieving SVR compared with short treatment. 
Discussion 
The results of our meta-analysis of RCTs shows that m HCV genotype 2 or 3 patients 
who obtain RVR at 4 weeks are most likely to benefit from a shorter therapy of (12-16 
weeks) as our meta-analysis shows that both treatment durations are not different 
in efficacy 
Trials that randomized patients at baseline favour standard therapy These results 
are likely a result of the proportion of patients who fail to achieve RVR at 4 weeks 
therapy and relapse after end of shorter therapy To put these data into perspective, 
we calculated the number needed to treat, which implicated that 94 patients 
should be treated and would achieve RVR with standard 24 weeks of treatment m 
order to obtain one more patient achieving SVR compared with short treatment 
The results are m Ime with those obtained by Andnulli et al.12 In that study, 
pooled SVR rates of HCV patients who achieved RVR showed that short or and 
standard treatment yield similar cure rates. RVR was the most discriminative 
factor, as patients who did not achieve RVR were more likely to fail with a shorter 
therapy (odds ratio 2.06 [95% CI 1 40-3 02]) 
However, they compared a mix of studies with different study designs, including 
RCTs, an open-label historical control study and results from a retrospective study. 
In addition, comparison was made among studies that differ m their randomization 
points of assigning patients in shorter or standard treatment We focused only 
on well designed RCTs because they are less susceptible to confounding, and we 
performed two meta-analyses for the different randomization points. 
Apart from RVR, it is possible that there are other (non-)virological factors, such as 
baseline characteristics including ethnicity, gender and liver histology, as well as 
ribavirin dosages that might also contribute to the therapeutic success of shorter 
therapy SVR rates were higher in most European and Asian studies m comparison 
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with the ACCELERATE trial and those from the NORDynamIC study group6·9. The 
HCV population included in Dalgard et al.10 and von Wagner et al.11 were relatively 
younger with mostly early stage fibrosis, whereas 25% of patients in ACCELERATE 
and 53% of patients in the NORDynamIC group had bridging fibrosis or cirrhosis. 
Different classification systems were used to stage fibrosis (for example, Metavir, 
Ishak and APRI scores); therefore, we could not perform a multivariate analysis to 
determine whether fibrosis stage influenced SVR in this meta-analysis. SVR rates 
were the highest in the study of Yu et al.,17 and there might be a few reasons for this 
difference. First, they included only HCV genotype 2 Taiwanese patients. Racial factors 
have been shown to influence the virological response even when standard treatment 
is given21·22. Second, the mean body weight was lower. Higher average doses of pegy-
lated interferon or ribavirin per kg body weight contribute to a higher SVR4'23'24. 
A previous study showed that there was no significant difference in SVR rates in HCV 
genotypes 2 and 3 patients for 24 weeks (or 48 weeks) with 800 mg/ day or 1,000/1,200 
mg/day ribavirin4. This suggests that the dose of ribavirin is less important for geno-
types 2 and 3 compared with 1 and 4. In our meta-analysis, we found that RCTs with 
weight-based dosages (800-1,400 mg daily)10'11·17-20 achieved higher SVR compared 
with fixed-dose (800 mg daily)6·9. This suggests that there might be a benefit, as 
higher ribavirin exposure contributes to higher SVR rates and lower relapse rates in 
shortened treatment regimes in patients. 
Furthermore, two types of pegylated interferon (a2a and a2b) were used in these 
studies. Eight RCTs used pegylated interferon-a2a and two trials used a2b, this 
might have had an influence on achieving SVR; however, there is little evidence to 
support the notion that one pegylated interferon is more effective than the other25. 
One abstract used conventional interferon in combination with ribavirin, which 
might lead to a lower SVR18. However, we performed a subanalysis that showed 
no difference in outcome. The duration of treatment in the abbreviated regimen 
varied across trials from 12 to 16 weeks. No difference in SVR was found between 
these weeks. 
Recently, an 8-week regimen of antiviral therapy has been investigated and yielded 
a very high relapse rate (67%) indicating the limitation of reduction of treatment 
below 12 weeks in patients with HCV genotype 2 who achieved RVR26. 
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Our meta-analysis has several limitations. First, we included three trials published 
as abstracts; therefore, we did not have complete data1820. Often, abstracts contain 
preliminary data and use efficacy analysis rather than intention-to-treat analysis to 
calculate outcomes. This approach can lead to overestimating a treatment effect. 
Another aspect is that we could not judge their methods and analyses because 
of the missing explaining text. However, exclusion of abstracts from the analysis did 
not affect the results. Second, we included only RCTs in our analysis. Although well 
designed RCTs are less susceptible to bias than other study designs, generalizability 
to real world practice is often limited. Third, these RCTs are not completely homo-
genous and might differ in baseline characteristics. We did not have access to 
individual patient data; therefore, we were unable to analyse potentially important 
predictors of outcomes such as body mass index, race and severity of baseline 
disease. Because of randomization, we surmise that there are no differences in 
both intervention groups. Fourth, the use different viral load cutoff levels for RVR 
and EOT among studies is a potential caveat. Cutoff values varied from <600 lU/ml, 
<50 ID/ml and <15 IU/ml and this could potentially affect the number of patients 
achieving RVR9·11. However, no effect was measured on SVR in this study9. Finally, 
as with all meta-analyses, this study has the potential limitation of publication bias. 
Negative results sometimes fail to be published. However, our data suggest that 
this does not play a role. The corresponding funnel plot is shown in Figure 4. 
Despite these potential limitations, our analysis provides important information for 
clinicians treating these patients and suggests that RVR is an important parameter 
in determining success of shorter therapy. This is underlined with the results by a 
large RCT by Mangia et al.8, which also concluded that a shorter course of therapy 
(12 weeks) is as effective as a 24-week course for patients with HCV genotype 2 or 3 
who have a RVR. This trial did not meet the inclusion criteria in our meta-analysis, as it 
lacked randomization for the variable duration group; patients with RVR were treated 
for 12 weeks and without RVR were treated for 24 weeks. Abbreviated regimens are 
less expensive, reduce exposure to side effects and might have tolerability advantages 
over a 24-week regimen. Shorter treatment duration can, in particular, reduce the 
incidence of delayed, mainly psychiatric, side effects. Moreover, compliance will be 
improved and there will be fewer drop-out patients because of adverse events 
when using shorter therapy. 
64 
Oplimi/ation of rurren! tioiiRtilis C, Ircnlrncnl Müla ,Ίη,ιΙγ-,ρ 
In conclusion, this study shows that for HCV genotype 2 and 3 patients achieving 
RVR at week 4, the efficacy of a shorter (12-16 weeks) treatment with pegylated 
interferon and ribavirin is not different from 24 weeks. Patients who do not achieve 
RVR at week 4 should receive at least 24 weeks of treatment. 
Acknowledgements 
This study was funded by an unrestricted grant from Schering-Plough, the manu­
facturer of Peglntron® and Rebetol® (pegylated interferon-a2b and ribavirin, 
respectively). 
Disclosure statement 
SS and JPHD received an unrestricted research grant from the Foundation for Liver 
Research (SLO) and Roche, the manufacturer of Pegasys® (pegylated interferon-a2a) 




1. L auer GM, Walker BD. Hepatitis C infection Ν Engl J Med 2001, 345:41-52 
2. Ghany MG, Strader DB, Thomas DL, et al. Diagnosis, management, and treatment of hepatitis C 
an update. Hepatology 2009; 49:1335-1374. 
3. De Bruijne J, Buster EH, Gelderblom HC, et al. Treatment of chronic hepatitis C virus infection 
- Dutch national guidelines. Neth J Med 2008; 66:311-322. 
4. Hadziyanms SJ, Sette H, Jr, Morgan TR, et al. Peginterferon alpha2a and ribavirin combination 
therapy m chronic hepatitis C: a randomized study of treatment duration and ribavirin dose. 
Ann Intern Med 2004; 140:346-355. 
5. Fontanges T, Beorchia S, Douvm C, et al. Safety and efficacy of combination therapy with 
peginterferon alfa-2a (40kD) and ribavirin in the outpatient setting: prospective analysis of 197 
patients with chronic hepatitis C viral infection. Gastroenterol Clin Biol 2007; 31 566-572. 
6. Shiffman ML, Suter F, Bacon BR, et al. Peginterferon alfa-2a and ribavirin for 16 or 24 weeks in 
HCV genotype 2 or 3 Ν Engl J Med 2007, 357 124-134. 
7. Zekry A, Patel Κ, Muir A, et al. Tinkering and tailoring with HCV therapy: can we get away with 
less? Hepatology 2004, 40 1249-1251. 
8. Mangia A, Santoro R, Minerva N, et al. Peginterferon alfa-2b and ribavirin for 12 vs. 24 weeks 
in HCV genotype 2 or 3. Ν Engl J Med 2005; 352.2609-2617. 
9 L aggmg M, Langeland Ν, Pedersen C, et al. Randomised comparison of 12 or 24 weeks of 
peginterferon a-2a and ribavirin in chronic hepatitis C virus genotype 2/3 infection. Hepatology 
2008,47.1837-1845. 
10. Dalgard O, Bjaro K, Ring-Larsen H, et al. Pegylated interferon alfa and ribavirin for 14 versus 24 
weeks in patients with hepatitis C virus genotype 2 or 3 and rapid virological response. Hepatology 
2008; 47:35-42. 
11. von Wagner M, Huber M, Berg T, et al. Peginterferonalpha- 2a (40KD) and ribavirin for 16 or 24 
weeks in patients with genotype 2 or 3 chronic hepatitis C. Gastroenterology 2005; 129 522-527. 
12. Andriulli A, Mangia A, lacobellis A, et al. Meta-analysis, the outcome of anti-viral therapy in HCV 
genotype 2 and genotype 3 infected patients with chronic hepatitis. Aliment Pharmacol Ther 
2008; 28397-404. 
13. Andriulli A, Dalgard O, Bjero K, et al Short-term treatment duration for HCV-2 and HCV-3 infected 
patients. Dig Liver Dis 2006; 38:741-748. 
14. Dalgard O, Bjero K, Helium KB, et al. Treatment with pegylated interferon and ribavarm in HCV 
infection with genotype 2 or 3 for 14 weeks: a pilot study. Hepatology 2004; 40:1260-1265. 
15. Moher D, Cook DJ, Eastwood S, Olkm I, Rennie D, Stroup DF. Improving the quality of reports of 
meta-analyses of randomised controlled trials: the QUOROM statement. Quality of Reporting of 
Meta-analyses. Lancet 1999; 354:1896-1900. 
16. Jadad AR, Moore RA, Carroll D, et al Assessing the quality of reports of randomized clinical trials: 
is blinding necessary' Control Clin Trials 1996; 17:1-12. 
66 
Optimization of current hepalilis C trodUnenl Mela analyses 
17. Yu ML, Dai CY, Huang JF, et al A randomised study of peginterferon and ribavirin for 16 versus 24 
weeks in patients with genotype 2 chronic hepatitis C. Gut 2007;56:553-559. 
18. Farooqi Jl, Farooqi RJ. Conventional interferon alfa-2b and ribavirin for 12 vs. 24 weeks in HCV 
genotype 2 or 3. Asian Pacific Digestive Week. 15-18 October 2007, Kobe, Japan. Abstract 218. 
19. Mecenate F, Barbaro G, Pellicelli A, et al. Comparison of peginterferon alfa-2a and ribavirin for 
12 or 24 weeks m patients with HCV genotype 2 or 3: the Cleo Trial. 58 t h Annual Meeting of the 
American Association for the Study of Liver Diseases. 2-6 November 2007, Boston, MA, USA. 
Abstract 1327. 
20. Bonardi R, Manca A, Tabone M, et al The efficacy of a 12 weeks course of pegylated interferon 
alpha-2b (Peg-IFN) and ribavirin (RBV) is similar to a standard 24 weeks course, regardless of basal 
viremic level. 9th Annual Meeting of the European Society for Clinical Virology. 3-6 September 
2006, Birmingham, UK. Abstract 246. 
21. Reddy KR, Hoofnagle JH, Tong MJ, et al. Racial differences m responses to therapy with interferon 
in chronic hepatitis C. Consensus Interferon Study Group. Hepatology 1999, 30787-793. 
22 Muir AJ, Bornstein JD, Killenberg PG, the Atlantic Coast Hepatitis Treatment Group. Peginterferon 
alfa-2b and ribavirin for the treatment of chronic hepatitis C m blacks and non-Hispanic whites. 
Ν Engl J Med 2004; 350:2265-2271. 
23. Manns MP, McHutchison JG, Gordon SC, et al. Peginterferon alfa-2b plus ribavirin compared with 
interferon alfa-2b plus ribavirin for initial treatment of chronic hepatitis C: a randomised trial 
Lancet 2001,358 958-965. 
24. Shiffman ML, Wilson M, Salvatori J, et al Treatment of chronic hepatitis C virus (HCV) genotype 1 
with peginterferon alfa-2b (PEGIFN), high weight based dose ribavirin (RVN) and epoetin alfa 
(EPO) enhances sustained virologie response (SVR). Hepatology 2005, 42-217. 
25. McHutchison J, Sulkowski M. Scientific rationale and study design of the individualized dosing 
efficacy vs flat dosing to assess optimal pegylated interferon therapy (IDEAL) trial determining 
optimal dosing in patients with genotype 1 chronic hepatitis C. J Viral Hepat 2008; 15:475-481 
26. Toyoda H, Kumada T, Kinyama S, et al. Eight-week regimen of antiviral combination therapy with 
peginterferon and ribavirin for patients with chronic hepatitis C with hepatitis C virus genotype 2 




Higher SVR rates after 
higher dosage of ribavirin 
in combination therapy 
for patients with hepatitis 
C virus genotype Ί and 4: 
a meta-analysis 
S. Slavenburg1 
M.G.H, van Oijen1 
R. Roomer2 
R.J. de Knegt2 
J.P.H. Drenth1 
ι 
Department of Gastroenterology and Hepatology, Radboud University Nijmegen Medical Centre, 
Nijmegen, The Netherlands ^Department of Gastroenterology and Hepatology, Erasmus University 
Medical Centre, Rotterdam, The Netherlands 
Current guidelines recommend weight based dosing of ribavirin for 
the treatment of patients infected with chronic hepatitis C virus (HCV) 
Several randomised clinical trials (RCTs) have been performed studying 
differences in sustained virological response (SVR) rates for fixed dose, 
weight-based and high dose ribavirin regimes in combination therapy 
We conduct a meta analysis of published RCTs to determine whether 
a higher ribavirin dosage is more effective in combination therapy for 
patients with HCV 
We performed a systematic search for literature that met our inclusion 
criteria Results were analysed according to intention to treat analysis 
Eight RCTs including a total of 6,525 HCV patients were analysed 
Meta-analysis for genotype 1 and 4 demonstrated a clear advantage 
for weight based dosing, the relative risk (RR) was 0 91 (95% CI 0 87 -
0 96, p=0 0001 ) In difficult-to treat genotype 1 patients higher dosage 
(up to 1,600 mg/day) was in favour of weight-based dose ribavirin 
with a RR of 0 80 (95% CI 0 63 - 1 01 , p=0 06) The overall analysis, 
including all HCV genotypes, demonstrated that SVR was similar 
between weight based (47%) and fixed (600 800 mg/day) dose 
ribavirin strata (44%), (RR of 0 93 (95%CI 0 81-1 07, p=0 31 )) 
In conclusion, higher dosing of ribavirin in HCV combination therapy, 
in particular, genotype 1 and 4 patients, achieves higher SVR rates 
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Introduction 
Hepatitis C virus (HCV) infection is a common cause of chronic hepatitis in the western 
world and leads to cirrhosis in up to 25% of infected patients over a period of 15-30 
years1. The main treatment goal in HCV is viral eradication thereby preventing pro-
gression of liver fibrosis and its complications. The most effective treatment for 
chronic HCV infection consists of the combination of peginterferon alfa-2a or alfa-2b 
and ribavirin. Duration and dosage of the individual components depend on HCV 
genotype and weight of the patient. Sustained virological response (SVR) rates in HCV 
patients vary from 42-46% in genotype 1 and up to 90% in genotype 2 and S24. 
In pooled data from two pivotal studies with peginterferon alfa-2a and ribavirin, 
the probability of achieving SVR for genotype 1 patients was influenced by ribavirin 
dose per kg body weight. A 40-50% increase in the probability of SVR was found with 
a dose increase of ribavirin from 12 to 16 mg/kg5. The effect of ribavirin was deemed 
to be independent of the type of pegylated interferon as combination of weight-
based (800-1,400 mg/day) ribavirin with peginterferon alfa-2b also leads to higher 
SVR rates compared to fixed dose (800 mg/day) ribavirin (34% vs. 29%). Ribavirin 
dosing up to 1,400 mg/day appears to be safe with similar rates of treatment 
discontinuation as conventional dosing6. 
There are a number of issues that need to be resolved in order to fully appreciate 
the role of ribavirin and ribavirin dosing. First, while higher ribavirin dosages 
appear to be advantageous for genotype 1 HCV patients, its relevance in patients 
who are highly sensitive to combination therapy, such as genotype 2 and 3 
patients, is unclear7. In addition, it is unknown whether monitoring of plasma 
levels might be beneficial. Recent studies have implied that ribavirin plasma levels 
can predict response rates, but the optimal target dose for ribavirin remains to be 
established 8"10. These issues are relevant as ribavirin is associated with reversible 
and dose-dependent haemolytic anaemia which frequently leads to dose reduction 
and discontinuation of ribavirin11. 
The purpose of this study is to systematically analyze all randomised controlled trials 
(RCTs), that compare fixed dose versus weight-based or weight-based versus higher 
dosage of ribavirin in (peg)interferon combination treatment in HCV. 
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Methods 
We performed a systematic literature search with predefined search terms for the 
period 2000 until January 2009 in a number of electronic databases. The mesh 
terms 'HCV OR hepatitis C', 'Ribavirin OR Rebetol® OR Copegus®' were entered to 
identify articles. Our search was limited to human adult randomized clinical trials 
that were published in the English language. We used the following databases: 
Medline (Pubmed), Web of science, clinicaltrials.gov and Cochrane Registry of 
controlled trials databases for articles and abstracts published. According to the 
QUORUM GUIDELINES we reported all steps in this meta-analysis12. 
RCTs were eligible if they compared fixed dose ribavirin or weight-based with high 
dosage of ribavirin in the treatment of HCV. Ribavirin was invariably given as part 
of the combination with peginterferon or interferon treatment. 
Exclusion criteria were studies that included patients with human immunodeficiency 
virus (HIV) co-infection, hepatitis Β virus co-infection, decompensated liver cirrhosis, 
hepatocellular carcinoma, haemodialysis, haemophilia, liver or renal transplantation. 
Studies that involved previously treated patients, non-responders or relapsers 
were excluded. 
Two reviewers (S.S. and R.R.) independently screened the titles and abstracts of all 
identified studies to identify RCTs that satisfied the inclusion criteria. On retrieving 
full text versions of relevant papers, an inclusion worksheet was applied to identify 
appropriate trials. Discrepancies were resolved by discussions between the authors 
of this meta-analysis. 
~ -1*1 -''l'i f ~·Ί 
All data from the selected studies were independently extracted using a standardized 
data-collection form, and entered in an electronic database. The following character­
istics were recorded: the first author's name; year of publication; study design; 
funding source; and population characteristics (gender, ethnicity, age, body mass 
index, fibrosis stage, HCV load). 
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Data were separately extracted for fixed dosage, weight-based and high dosage of 
ribavirin, number of subjects; duration of treatment; dosages and type of peginter-
feron and ribavirin; end of treatment response (EOT) and SVR. 
We took the achieved SVR rates as the primary outcome of this meta-analysis. SVR 
is defined as a negative result on a qualitative PCR assay for HCV-RNA, 6 months after 
the end of treatment. The secondary end-point EOT, is defined as a negative result on 
a qualitative PCR assay for HCV-RNA after termination of treatment (24 or 48 weeks). 
Duration of therapy varied from 24 weeks in HCV genotype 2 and 3 to 48 weeks in 
genotype 1 and 4 of combination treatment. One trial randomized genotype 1, 2, 3 
and 4 in 24 to 48 weeks of treatment4. 
yìt ist 'xj l i'i i\) , 
SVR rates were pooled and analysed on an intention-to-treat basis. Statistical hetero-
geneity between trials was tested with Chi-squared tests (whereby ρ < 0.1 indicates 
significant heterogeneity) and quantified using the I2 statistic (whereby a value of 
25 percent is considered low, 50 percent moderate, and 75 percent high)13. 
Relative risks (RR) were calculated with 95% confidence intervals (CI) using a random 
effects model. Forest plots of individual study results were created by plotting the RR's 
against sample size to detect asymmetry in the distribution of trials. The number need­
ed to treat was calculated with 1 divided to the absolute risk reduction (ARR). Through 
a funnel plot the possible presence of publication bias was assessed. All statistical 
analyses were performed using Review Manager (RevMan) Version 5.0 for Windows. 
Results 
CJviicK Ipn ,Ίοί: of trial3 
We identified 8 RCTs representing a total of 6,525 HCV patients for the meta-analysis. 
Six trials were international multicentre studies3·4·6 1 5 1 7, the others were single 
centre trials1 4 1 8. Six studies were open-labelled3 '6 1 4 1 6 1 8 and 2 were double-blinded 
randomised trials"1 5. Details of selection of RCTs are shown in figure 1. 
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Characteristics of the studies included and the corresponding study populations 
are given in table 1. Duration of therapy varied from 24 weeks in HCV genotype 
2 and 3, or 48 weeks in genotype 1 and 4 of combination treatment. One trial 
randomised genotype 1,2,3 and 4 over 24 or 48 weeks of treatment4. For the 
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meta-analysis only data from the 48 weeks treatment regimens for genotype 1 and 
4 from this trial were included4. Different types and dosages of (peg)interferon 
a-2a and a-2b and ribavirin were used in trials (table 1). Two studies used a fixed 
but lower than conventionally used dosages (500-600 mg/day) of ribavirin. These 
two studies were excluded from the primary analysis as this dosage is currently 
considered to be suboptimal. However, the extracted data were included in the 
subgroup analysis1618. 
K';ta a'iji, - ^ 3 d^id l f trni 
Table 2 depicts the data of primary and subgroup analysis with the number of trials 
included, sample size in the treatment and control group, relative risk with 95% CI., 
test for association with the P-value of chi-square statistic, number needed to treat 
to benefit one additional patient and statistical heterogeneity between trials as 
evaluated by a Cochran Q-test. The trials in four analyses were homogeneous (P-
value for heterogeneity > 0.1), and none of the analyses showed publication bias as 
assessed by visual inspection of funnel plots. 
Genotype 1 and 4 
It was found that weight-based ribavirin led to significantly higher SVR rates in geno­
type 1 or 4 patients compared to fixed dose ribavirin (38% vs. 31%). The RR was 
0.91 (95% CI 0.87 - 0.96, ρ=0.0001)3Λ6'16, which favours weight-based dose ribavirin 
in genotype 1 or 4 patients (figure 2). The number needed to treat in this group is 
15, this means that 15 patients should be treated with weight-based ribavirin to 
obtain one more patient achieving SVR compared with fixed dosage of ribavirin in 
genotype 1 or 4 patients. 
Higher dose ribavirin genotype 1 
Two trials compared high dose with conventional weight-based ribavirin in genotype 
1 restricted HCV (figure 3)1 4'1 5. A pooled analysis demonstrated that higher dosages 
of ribavirin were non-significantly better than weight-based dose of ribavirin in terms 
of SVR: 42% vs. 27%; RR of 0.80 (95% CI 0.63 - 1.01, p=0.06). 
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Author,year of No of Trial 
publication patients type 
[reference] 
Publication Population Race PEG) IFN type FD RBV dosage WB RBV 
type Genotype 1 % Caucasian Dosage (mg/day) Dosage 
FD vs WB % (mg/day) 
Fixed High WB RBV 
high RBV Dosage 
Dosage (mg/day) 
(mg/day) 
Hass, 2004[18] 29 RCT 
Huber, 2005(16] 27 RCT 
Helblmg, 2006(17] 124 RCT 
Letter 25 33 unknown 
Full paper 56-54 unknown 
Full paper 47-53 unknown 
*a-2a, 6 MU 
*a-2a, 6 MU daily 28 
days, 6 MU 11 w 






Jacobson, 2007[6] 4,223 RCT 
Hadziyanms, 2004(4] 809 RCT 
Full paper 62-61 79 
Full paper 69 62 89 
a-2b, 1 5 μg/kg/wk 800 
a-2a, 180 μg/wk 800 
800 1,200 
1,000/1,200 
Manns, 2001(3] 1,025 RCT Full paper 68 68 
Shiffman, 2007(14] 100 RCT Full paper 100-100 59 
a-2b, 1 5 μg/kg/wk 
or 1 5 for 4 weeks 
and then 0 5 
μg/kg/wk 
for 48 weeks 
α 2 b, 1 5 μg/kg/wk 
800 1,000/1,200 
800 1,400 1,000-1,600 
Fried, 2008(15] 94 RCT Full paper 100-100 71 a-2a, 180 Mg/wk 1,200+ l,600t 
Fried, 2008(15] 94 RCT Full paper 100 100 66 a-2a, 270 μg/wk 1,200+ 1,600+ 
RBV is ribavirin FD is fixed dose and WB is weight-based dose (PEG) IFN is (peg)interferon 'interferon 11 w thrice weekly, + fixed dose of ribavirin, ^Patients were treated 
with 6 MU IFN α 2a, daily for 6 weeks, then with 6 MU 11 w for 6 weeks and for the remaining 36 weeks with 3 MU 11 w X weight based low dose ribavirin 
Table 2. Results of meta analyses of SVR data for genotype and different dosage reg mens of nbav nn 
Type of analysis 
Overall analysis, 
(all genotypes) 





Dosage of RBV 
Fixed 500-600 RBV 
vs WB RBV 
Fixed 800 mg vs 
WBRBV 





























0 80(0 62-102) 
0 91 (0 87-0 96) 
103(0 94-112) 

















Ρ value/ I2 ""for 
heterogeneity* 
0 010/67 
0 14 / 49 
0 3 7 / 4 
0 16/42 
0.74/0 
0.002 / 84 
RBV is ribavirin, WB is weight based dose of ribavirin, 
tTest of association with the value of chi-square statistic, when Ρ is < 0 05 virological responses between treatment vs control groups were significant 
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Figure 2. Forest plot ol SVR rales of weight based versus fixed dose ol ribavirin in HCV genotype 1 
and 4 patients 
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This figure shows the primary analysis of SVR rates m difficult-to-treat genotype 1 The relative risk of 
0 80 (95% CI 0 63-1 01) shows a favour for high dose of ribavirin in combination treatment 
Genotype 2 and 3 
There were four trials which compared weight-based with fixed dose of ribavirin in 
genotype 2 and 3 patients3'4·6·17. The results in terms of SVR rates were similar: 67% 
versus 64% 3 Λ 6 ' 1 4 . Collectively, use of weight-based ribavirin is equally effective as 
fixed dose of ribavirin (RR of 1.03 (95% CI 0.94 - 1.12 p=0.57)). These data suggest 
the advantage of higher ribavirin dosages is restricted to genotype 1 or 4 patients. 
Lower fixed dosage of ribavirin 
We found two studies which compared a lower fixed dose (500-600 mg/day) 
ribavirin versus weight-based dosage of ribavirin16·18. Pooled SVR rates in lower 
fixed dose ribavirin trials were generally lower 41% than with weight-based 
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dosing (51%). Thus, fixed low (500-600 mg/day) ribavirin seems disadvantageous -
although not significant - compared to weight-based ribavirin with a relative risk 
(RR) of 0.83 (95% CI 0.63 - 1.09 p=0.17). 
End of treatment response 
EOT in the overall group (all genotypes) was reported in 5 trials. The EOT rates were 
comparable among the various ribavirin dosing schemes3-4'616·18. Weight-based 
dose ribavirin had a comparable EOT compared to the fixed dose ribavirin (60 vs. 
59%; RR: 1.01 (95% CI 0.89 -1.14, p=0.90). 
Three trials reported EOT rates in genotype 1 or 4 patients. These trials yielded a 
pooled EOT of 58% in the weight-based versus 53% in fixed dose ribavirin: pooled 
RR of 0.93 (95% CI 0.71 - 1.22, ρ=0.59)3 Λ 6. Higher dosages of ribavirin were more 
effective than weight-based dosing as 55% achieved EOT relative to 43% in lower, 
fixed, dosages (pooled RR 0.78 (95% CI 0.62 - 0.98, p=0.03)14·15. In addition, although 
not significant, higher relapse rates were seen with weight-based ribavirin compared 
to high dose (58% vs. 20%, p=0.40). 
Adverse events: anaemia 
Three RCTs indicated that the differences in ribavirin dose regimens did not affect 
haemoglobin concentrations, while one study did not give these data 3 · 6 1 6 1 7 . 
Weight-based dosing generally led to a more profound decline of haemoglobin 
than fixed dosing. For example, significant anaemia (Hb <10 g/dL) is seen in 15.4% of 
patients on weight-based ribavirin compared to 5.4% with fixed dosing" and 19.3% vs. 
12.5% in another study6. Higher dosage of ribavirin (1,000-1,600 mg/day) did not lead 
to a greater decline of haemoglobin in comparison to weight-based dosing1 4 1 5. 
Discussion 
The results of our meta-analysis of HCV treatment RCTs indicate that weight-based 
dose ribavirin is more effective in genotype 1 and 4 in achieving SVR than fixed dose 
ribavirin. Weight-based dosing of ribavirin does not improve SVR rates in genotype 
2 and 3 patients. The effect of weight-based dosing is probably dual: this strategy 
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allows more HCV patients to obtain viral negativity at end of treatment, and it 
reduces the risk of relapse. 
To put these data into perspective the number needed to treat was calculated, 
which implicates that 15 patients with genotype 1 or 4 should be treated with 
weight-based ribavirin dose treatment to obtain one more patient achieving SVR 
compared with fixed dose of ribavirin. 
On the basis of the current meta-analysis we favour fixed ribavirin (800mg/day) 
for genotype 2 or 3 patients. Reductions to 400 mg/day in these HCV patients 
appears to be possible, as one RCT documented dose reductions of RBV (up to 400 
mg/day) which did not compromise treatment efficacy7. While we found that 
weight-based ribavirin dosing increases the chance of curing HCV, several studies 
extended this concept and have tried even higher ribavirin dosages. We found data 
that suggests that 1,600 mg/day further increases SVR rates in HCV genotype 
1 patients1415. A bold step forward was made by a study that demonstrated 
that dosing ribavirin at twice the recommended dose (mean 2,540 mg/day, range 
1,600-3,600 mg) resulted in a 90% SVR in a cohort of 10 HCV genotype 1 patients. 
All patients suffered from severe anaemia, which was managed with concomitant 
epoetin beta and blood transfusion23. 
Anaemia is frequently an issue with ribavirin, as it causes haemolysis18. Most 
adverse events reported in the studies used in the meta-analysis were mild to 
moderate in severity and all adverse events were typical of those previously 
reported for (peg)interferon and ribavirin and they were similar among the 
various ribavirin dosage regimens19. Indeed, careful patient management is required 
with higher dosage of ribavirin to minimize the effects of haemolytic anaemia1415. 
Erythropoietin doses from 9,000 to 60,000 ID/week have been used in order keep 
the highest possible RBV doses and this strategy has proven to be effective in terms 
of maintaining ribavirin doses without causing anaemia14'2022. In our meta-analysis, 
in two studies using a higher dose of ribavirin erythropoietin was administered to 
patients14·15. 
Many studies have been performed to establish which dosage of ribavirin is the 
most effective and safe for HCV patients3'4·6"·14·15'16"18'23 The strength of this study is 
that we performed the first meta-analysis on this topic, which statistically shows 
the benefit of higher dosage of ribavirin in genotype 1 and 4 patients. In the overall 
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analysis HCV genotype 2 and 3 patients were included m these trials, however, the 
association between SVR and genotype is well k n o w n 3 4 6 1 7 To avoid possible bias 
we performed several meta-analyses of these studies (table 2) 
On the other hand, our meta-analysis comes with several limitations First, the 
primary outcome of our meta-analysis was SVR and secondary was EOT, however 
we did not include other time points such as rapid virological response (RVR) 
and early virological response (EVR), due to the lack of data from these studies 
Furthermore, as we lacked access to individual data from the studies we could not 
investigate a possible relation between total ribavirin exposure and SVR Second, 
Two studies used lower fixed ribavirin dosage (500-600 mg/day) Nowadays this 
dosage is considered to be suboptimal, and we excluded these studies from the 
primary analysis1618 Third, different pegmterferon regimens were used in the trials 
which might influence the SVR rates On the other hand pegmterferon alpha-2a 
and pegmterferon-alpha 2b seem to be equally effective in HCV treatment24 
Fourth, we included only RCTs in our analysis Although well-designed, RCTs 
are less susceptible to bias than other study designs, generalization to real-world 
practice is often limited 
Finally, these RCTs are not completely homogenous and may differ m baseline 
characteristics We did not have access to individual patient data, therefore we 
were unable to analyze potentially important predictors of outcomes such as body 
mass index, race and severity of baseline disease Because of randomisation we 
suspect that there are no differences between both intervention groups None of 
the analyses showed publication bias as assessed by visual inspection of funnel 
plots, however there were too few studies to perform a rank correlation test 
Two pilot studies which used higher doses of ribavirin prompted the development 
of two large trials termed PROGRESS and the VIRID s t u d y 7 8 2 3 2 5 2 6 They will 
attempt to confirm the hypothesis that treatment with higher doses of ribavirin 
(1,400-1,600 ribavirin mg/day in PROGRESS and 1,000-3,000 ribavirin mg/day in the 
VIRID study) is more beneficial in difficult-to-treat genotype 1 and 4 patients2 5 2 6 
Although the data from our meta-analysis suggests otherwise, there is an ongoing 
clinical trial, DARGEN, which examines whether a higher dose of ribavirin benefits 
HCV genotype 3 patients27 
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How should we interpret the current data against the backdrop of the advents of 
newer classes of drugs, such as protease and polymerase inhibitors? Pivotal phase 
III studies with Telaprevir and Boceprevir have shown that ribavirin is a necessary 
component of the HCV combination therapy, therefore it is to be expected that 
peginterferon and ribavirin will serve as the backbone of triple drug regimens in the 
foreseeable future2831. Therefore, optimizing peginterferon and ribavirin dosages 
remains an important goal. 
Higher dosage of ribavirin in genotype 1 and 4 patients results in higher SVR rates. 
It is crucial to optimize ribavirin dosage in order to achieve higher SVR rates and to 
minimize relapses. 
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Ribavirin is an essential component in the treatment of chronic hepatitis 
C (HCV) infection Though ribavirin dosage is weight based, data in 
literature suggests large interpatient variability in plasma ribavirin 
concentration Recent studies indicate that higher ribavirin exposure 
results in higher sustained viral response rates Monitoring ribavirin 
concentration is suggested in literature, however, it is unclear at what 
time point during treatment, ribavirin plasma concentrations should be 
monitored 
The aim of this study was to investigate the association between early 
plasma ribavirin concentrations and ribavirin dosing with steady state 
(Cgs) concentration and the inter and mtrapatient variability in plasma 
ribavirin concentration in clinical practice 
A prospective observational cohort study in HCV patients who received 
pegylated interferon in combination with oral weight based ribavirin 
(12 15 mg/kg) twice daily was performed Ribavirin trough plasma 
concentrations at week 1 ,2 ,4 ,8 , 12, 16, 20 and 24 were studied as 
determined by a validated high-performance liquid chromatography 
(HPLC) assay 
In total 53 patients (37M, 16F) with a mean age 51 years (range 26-68 
years) were included and 209 samples were collected There was 
a significant correlation between week 2 as well as week 4 and 
plasma ribavirin Css(r=0 589 and r=0 714, p<0 05, resp ) Ribavirin 
Css was reached at week 8 of HCV treatment There was no correlation 
between dosage in mg/kg and Css(r=0 181, p=0 263) The coefficient 
of variation (CV) of plasma ribavirin concentrations at week 8 and after 
between and within patients was 43% and 13%, respectively 
In conclusion, nbavm steady state concentration in HCV-mfected patients 
can be predicted by measurement of early ribavirin concentration 
Ribavirin pljsma concentralion m hepatilib C Iherapy 
Background 
The combination of ribavirin with pegylated interferon (alfa-2a or alfa-2b) (Peg-IFN) 
given for 24-48 weeks is currently recommended as standard therapy for the 
treatment of chronic hepatitis C virus (HCV) infection.1 
Ribavirin is considered to be a pivotal factor for the cure of HCV. First, adding 
ribavirin to interferon greatly increases the likelihood of a sustained virological 
response (SVR).23 Second, ribavirin lowers relapse rates.4 Third, the success of 
the novel antiviral STAT-C (specifically targeted antiviral therapy for HCV) drugs 
depends on the addition of ribavirin.5·6 Finally, higher ribavirin dosages increase 
the likelihood of SVR.710 
The main limitation of ribavirin is its narrow therapeutic window. Ribavirin is 
associated with dose-dependent hemolytic anemia. It is, therefore, paramount to 
establish a therapeutic window for ribavirin plasma concentrations that balances 
the antiviral efficacy with adverse effects. Current practice suggests that ribavirin 
is to be administered as a weight-based regimen. However, ribavirin has a large 
distribution volume (approximately 2,000 L) and there are large inter-individual 
differences in concentrations.1112 Perhaps as a consequence, merely adjusting 
ribavirin dosage for weight, does not consistently predict plasma concentrations. 
Yet, it has been suggested that higher plasma ribavirin concentrations are associated 
with higher SVR rates.1319 Thus, it appears important to dose and adjust according 
to plasma concentrations rather than dosing based on patients' weight. This concept, 
therapeutic drug monitoring (TDM), could be potentially useful to optimize ribavirin 
dosing. However, it is unclear at what time point during treatment ribavirin plasma 
concentrations should be monitored. Literature is divergent on this issue. Some 
studies suggest measuring levels at week 4, others show a clear correlation between 
SVR and week 8 and 12, when steady-state is reached.12'15·16·18 Assessment prior to 
week 4 is suggested by some, as this would allow early adjustment of ribavirin dosing, 
even if steady state is not yet reached.14·20 Since ribavirin has an average elimination 
half-life of approximately 300 hours, small differences in timing of collecting samples 
are unlikely to influence the results.11 
We hypothesized that early measurement of ribavirin plasma concentration would 
predict steady-state. Therefore, we performed this study in order to clarify which 
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factors determine the variability of ribavirin plasma concentrations in clinical 
practice and to assess if early levels can predict later steady-state concentrations. 
Methods 
Γ^ i_jh -J'I J patonts 
We conducted a prospective, observational study that started in July 2007 and lasted 
until August 2009. The study took place in one university centre and two general 
hospitals in the Netherlands. 
All HCV and HCV/HIV co-infected patients, irrespective of genotype or co-morbidity, 
treated with combination therapy of ribavirin (Rebetol or Copegus) and Peg-IFN 
(alfa-2a or alfa-2b) and who were attending the outpatient clinic of one of the three 
hospitals were asked to participate in this study. Patients received once weekly 
Peg-IFN subcutaneously in combination with oral weight-based ribavirin (12-15 
mg/kg) two times daily, following international and local guidelines.21 Routine 
monitoring during hospital visits included viral load at week 0 , 1 , 2, 4, 8,12,16, 20 
and 24, complete blood count, clinical chemistry, renal function, adverse events 
monitoring and body weight assessment. No dose adjustments during the study 
were made based on plasma ribavirin concentrations. 
This study was conducted following local ethical considerations and the principles 
outlined in the declaration of Helsinki. 
Ribavirn moasirompnt 
At standard hospital visits, one additional blood container was collected for 
measuring plasma ribavirin concentration. Where possible, ribavirin trough 
samples were collected. Ribavirin plasma samples were collected in a heparinized 
vacutainer tube and were stored at -40°C until analyzed (ribavirin is stable for 
minimal 2 years in this storage condition). The samples were analyzed in a batch 
once monthly. 
Plasma concentrations of ribavirin were analyzed by a procedure used by D'Ävolio 
et al.22 with slight modifications. In brief, 1.5 mL acetonitril was added to 125 μ ι 
of plasma. The sample was mixed on a vortex mixer for 1 minute, followed by 
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centrifugation at 11,000 rpm for 5 minutes. Afterwards, the organic phase was 
evaporated at 37 °C under a gentle stream of nitrogen gas, and reconstituted in 125 
μ ι of mobile phase (20 mM phosphate buffer pH 3.23). 25 μ ι of the resulting solution 
was run on a 4.6*150 mm Atlantis® T3 5 μπι reversed phase CIS column (autosampler 
columnoven 35 °C, flow rate 1.0 mL/min) and ribavirin was detected by use of a UV 
detector (λ 235 nm) (UV2000 ThermoFisher Scientific, Breda, The Netherlands). 
The range of the assay that was used is: 0.3-12.0 mg/L. This method was validated 
according to current ICH and FDA guidelines. 
Sitjli:,lKV]l ana^sis 
Variables were expressed as median or mean with a range. Ribavirin concentrations 
were recorded as median with interquartile range (IQR). The Wilcoxon signed-rank 
test was used to compare ribavirin concentrations at different time points in order 
to determine ribavirin steady-state (Css) concentration. The time of Css is defined 
as the moment where no significant difference was found with the following time-
points. Correlations between ribavirin concentration, ribavirin dosage (mg/kg) and 
ribavirin steady-state plasma concentrations were calculated according to the 
Spearman's rho test. The association between potential predictive parameters 
of ribavirin steady-state were examined by univariate and multivariate linear 
regression analysis. All p-values were considered significant if the p-value was less 
than 0.05. All statistical analyses were performed using SPSS for Windows, version 
14.0 (SPSS, Chicago, IL). 
Results 
209 plasma samples for ribavirin measurement of a total of 53 included patients 
(37 men and 16 women) were collected. Baseline characteristics and treatment 
regimens of 53 patients included are given in Table 1. Six patients were HCV/HIV 
co-infected. Three patients were excluded from the analysis because of impaired 
renal function or use of erythropoietin. 
Renal function was normal in all patients. 
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Table 1 Basel ne c hararlenslics of the 53 palienls 
Characteristics Results 
Mean age - years (range) 
Male gender - η (%) 
Median weight (kg, range) 
Median serum Creatinin (μιτιοΙ/Ι., range) 
Median serum hemoglobin (g/dL, range) 
Median serum HCVRNAt 
IU/mlt (range) 
>600,000IU/ml-n(%) 






PEG-IFNa2a§ and ribavirin - η (%) 
PEG-IFNa2b§ and ribavirin - η (%) 
Mean dosage ribavirin mg/kg (range mg/kg) ¥ 
Median number of samples per patient (range) 
Median time after previous ribavirin dose, hours (range) 
51 (26-68) 
37 (70) 
72 8(50 2-113)* 
74 6 (54 124 6) 
14 7(10 4-18 0)* 
1*10 6(4·10 37*10 7) 
29 (55) 




11 (20 7) 
27(51) 
26 (49) 
13 5 (9 6 27 6) 
2 5 (1-4 5) 
6 5 (1 1 15 9) 
*49 patients, thepatitis C virus ribonucleic acid, flU/ml is international units per milliliter, §pegylated 
interferon a2a or a2b ¥Mean daily ribavirin dose (mg/kg) 
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Ph^rrrdCCwneTcs 
Median plasma ribavirin concentrations at week 1 to week 24 of therapy are 
depicted in figure 1. Ribavirin concentrations showed an asymptote at week 8 of 
therapy and week 8 values showed significant differences with concentrations at 
week 1, 2 and 4 (p <0.05). After week 8 there was no significant change in ribavirin 
concentrations, therefore, CSs concentration in this cohort is depicted as the median 
plasma concentration from week 8 and onwards. Intra- and interindividual variability 
of ribavirin concentrations at week 8 and later was 13% and 43%, respectively. 
There was a significant correlation between ribavirin concentrations at week 2, 4 
and CSs (r=0.589 and r=0.714, p<0.05, respectively) (Figure 2a,2b); in contrast, no 
correlation was found between week 1 and Css (r=0.214, p=0.366). In figure 2c 
the observed ribavirin CSs and the predicted Css at week 2 and 4 were compared. 
This figure shows, that the prediction of ribavirin CsS with the formula at week 4 
is more accurate than the prediction at week 2, with a bias of -2.69% (IQR 25-75%: 
-14.42-17.02) and -1.85% (IQR 25-75%: -18.18-13.57), respectively. Ribavirin CsS 
was significantly correlated with baseline serum Creatinin concentrations (r=0.403, 
p=0.015). In contrast, no correlation was found between ribavirin dosage mg/kg 
and Css (r=0.181, p=0.263). A total of 11 (24%) patients had ribavirin CSs < 2.0 mg/L 
and 17 (38%) <2.5 mg/L. 
Due to strong correlation (multicollinearity) between week 2 and 4 plasma ribavirin 
concentrations (r= 0.762, p= 0.000), we only added week 4 in the multivariate linear 
regression model. After adjustment, week 4 ribavirin was the only remaining factor 
that was independently associated with ribavirin Css. (Table 2) 
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Median plasma ribavirin concentrations with interquartile range (IQR) during 24 weeks of treatment 
of HCV patients included in this cohort. Steady-state (Css) concentration is depicted as the median 
plasma concentration from week 8 and onwards. 
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R 5<ι Linear = 0.357 
0.00 0.SO 1,00 1,50 2,00 2,50 3,00 3,50 
Cone RBV week 2 (mg/L) 
Through this formula: ribavirin steady-state = 1.164+0.755*ribavirin concentration at week 2 
(mg/L), the ribavirin plasma steady-state concentration can be calculated. 
Ribavirin plasma concentration in hepatitis C therapy 






Cone RBV week 4 (mgiL) 
Through this formula: ribavirin steady-state = 0.734+0.804*ribavirin concentration at week 4 
(mg/L), the ribavirin plasma steady-state concentration can be calculated. 
Figure 2c. The observed ribavirin steady-state (C ) concentration compared with the predicted ribavirin 
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Predicted Css R8V concentration week 4 irrg/Lj 
RSq Linear = 0.371 
Predicted Css RBV concentration week 2 (mg/L) 
Predicted Css RBV concentration (mg/L) 
Table 2. j ' ear rogrcssicn araiysis o' the preo cl en cl 'loavinn steady stalo w 'h oaseiine characl"risiics 
Multivariate linear regression analysis 
p-value 95% Cl 
Ribavirin concentration at week 4 (mg/L) 
Gender (M/F) 
Body weight (kg) 
Age (years) 
HCV load (lU/ml) 
Genotype (lor 4=1) 
Weight-adjusted ribavirin (mg/kg) 
Ribavirin dose (mg) 
Baseline Creatinin (μιτιοΙ/Ι.,) 



















(0 133-1 416) 
(-1 300-1 337) 
(-0 139-0 109) 
(-0 029-0 032) 
(-1024-0 428) 
(-0 641-0 896) 
(-0 638-0 509) 
(-0 009-0 010) 
(-0 012-0 025) 
(-1 094-0 699) 
Results represent the coefficient of regression and the p-value of each parameter. P-value <0.05 is marked bold. 
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Discussion 
We show that ribavirin steady-state concentrations can be predicted by early 
measurement of ribavirin concentrations m week 2 and week 4. In addition, we 
show that m a regular clinical setting C55 plasma concentrations of ribavirin are 
reached 8 weeks after start of HCV combination therapy. 
The possible clinical implication of our results is that adjustment of the ribavirin 
dose early during treatment can potentially lead to higher ribavirin Css A recent 
study found that the area under the curve AUCo -> 4h and AUCo -¥ UH of ribavirin 
plasma exposure after the first dose at day 0 was positively related to SVR 1A In 
this context, measuring early ribavirin concentrations might be helpful to tailor 
ribavirin dose individually to maximize the highest probability to reach SVR 
Indeed, an optimal therapeutic range of 2 0-2.5 mg/L at week 4 of HCV therapy has 
been suggested.20 This concept is confirmed by the finding that ribavirin plasma 
trough concentration <2.5 mg/L at week 4 is a negative independent predictor 
for relapse after stopping HCV treatment2 3 This data emphasizes that adequate 
ribavirin exposure is key m preventing relapse. Notably, 75% of patients from our 
cohort did not reach a ribavirin concentration of 2.5 mg/L at week 4 This suggests 
that with the current standard weight-based ribavirin dosing regimen, insufficient 
ribavirin concentrations are reached m many patients 
Which requirements do we need to meet in order to benefit from therapeutic drug 
monitoring? First, our data show that ribavirin concentrations are widely variable 
among different individuals with a low mtra-patient variation in plasma ribavirin 
concentrations. We found no correlation between ribavirin dosage m mg/kg and 
ribavirin steady-state concentrations These findings contribute to the concept of 
therapeutic drug monitoring for this drug 
As with all studies, our research comes with certain limitations First, this study was 
conducted in daily clinical practice, and as a consequence at some time points, riba­
virin trough plasma concentrations were not collected However, given ribavirin's 
long elimination half-life, variability in timing of sample collection is less relevant 
The correlations between week 2, 4 and Css are strongly significant. However, this 
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model cannot predict the plasma ribavirin C55 precisely, since part of the variation 
probably depends on other factors Nevertheless, week 2 and 4 concentrations can 
be used for early dose changes m order to reach the required Css level as soon as 
possible In line with these observations is that at least half of the patients in the 
lowest quartile of ribavirin plasma concentrations at steady-state were also in the 
lowest quartile of ribavirin plasma concentrations at week 2 (5/10) or week 4 (5/8). 
In clinical practice, ribavirin plasma concentration monitoring is currently not 
common practice This calls for future studies that verify whether dose adjustment 
of ribavirin in early weeks of HCV treatment lead to a higher CS5 and higher SVR rates 
In conclusion, we show that ribavirin steady-state concentrations in HCV-mfected 
patients m general are reached in week 8 and can be predicted by measurement at 
week 2 and 4 
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The introduction of pegmterferon and ribavirin (an oral nucleoside analogue) for 
chronic hepatitis C has led to the concept that hepatitis C virus (HCV) infection is a 
curable disease Not all HCV patients respond to therapy, and especially genotype 
1 and 4 patients with a high baseline viral load fare poorly Given the low sustained 
virological response (SVR) rates m genotype 1 patients (currently approximately 
50%), improvement of treatment efficacy is a major challenge The exact mechanism 
of ribavirin m HCV is not well understood There appears to be no direct inhibition 
of HCV replication, but there is rapid and lethal mutation of virions. In addition, 
there is depletion of intracellular guanosme triphosphate, necessary for viral 
RNA synthesis1 Several studies indicated that optimal ribavirin dosage is essential 
m achieving SVR2 A recent trial showed significantly higher SVR m patients 
receiving 15.2 mg/kg/day ribavirin compared with 13 3 mg/kg/day ribavirin, 
both m combination with pegmterferon alpha-2b3 A small pilot study, m which 
10 genotype 1 patients were treated with ribavirin dosages up to 3,600 mg/day 
plus pegmterferon alpha-2a, led to 90% SVR4 These data provide the rationale 
of a Dutch nation-wide investigator-initiated study m HCV the VIRID study 
We propose a randomised controlled clinical trial that aims to compare the current 
standard therapy with a regimen that includes double dosage of ribavirin (figure 1) 
Patients will be randomised to receive either 25-29 (mean 26.2) mg/kg/day ribavirin 
(Copegus, Roche) or 12-15 (mean 13.3) mg/kg/day Both groups will receive once 
weekly 180 μg pegmterferon alpha-2a (Pegasys, Roche) Treatment duration is 48 
weeks, with a follow-up of 24 weeks. Ribavirin is associated with a dose-dependent 
anaemia and management of this side effect is important5. We will treat all patients, 
regardless of ribavirin dosage, with epoetin beta (NeoRecormon, 30,000 Ill/ml/ 
week, Roche) once Hb drops below 6 8 mmol/l Patients with <2 loglO drop of HCV 
RNA at week 12 or HCV RNA positivity at week 24 will discontinue treatment. We 
made the following assumptions, high-dose ribavirin yields 67.5% SVR, based on 
cautious estimation of 20-25% improvement compared to standard treatment 
With a two-sided 5% significance test, a power of 80% and an estimated dropout 
rate of 10%, this study requires 85 patients m each arm 
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Figure 1 . Study design 
Screening 
Screening 
180 Mg Peginterferon alfa-2a QW 
Ribavirin 26.2 mg/kg/day 
180 Mg Peginterferon alfa-2a QW 
Ribavirin 13.3 mg/kg/day 
î î Î 
Weeks -4 0 12* 
i drop < 2loa^: STOP TREATMEN 
Follow-up 
24** 48 72 
3NA positive by qualitative assay: STOP TREATMENT 
We ask Dutch physicians who see and treat HCV patients to participate in this trial. 
Patients will be treated by their own physician in their own centre. This nation-wide 
HCV project will include 20-30 academic and non-academic participating centres. 
Recruitment will start in March 2008 and will continue until March 2009. The main 
inclusion criteria include: serological evidence of chronic hepatitis C genotype 1 or 
4, treatment naive, high viral load (>400,000 lU/ml) and a liver biopsy within three 
years of screening. The main exclusion criteria include: signs of decompensated liver 
disease, HBV or HIV co-infection, evidence of hepatocellular carcinoma, significant 
cardiovascular, pulmonary or renal dysfunction, severe psychiatric disorder, pregnan-
cy or breastfeeding. Since there is a clear need for optimising the current anti-HCV 
therapy, different strategies have been proposed: Induction dosing of peginterferon, 
prolonging therapy duration, increased weight-based ribavirin dosing and novel anti-
viral agents. Induction dosing of peginterferon did not lead to a major Improvement 
of treatment outcome and data on prolongation of treatment duration are conflicting. 
The new agents (e.g.: protease Inhibitors and polymerase inhibitors) seem promising 
but will not be available for the coming years, development of antiviral resistance may 
temper initial expectations, and the tandem peglnterferon/rlbavlrln will remain the 
template for therapy. 
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These considerations have led to development of the VIRID study. This study is 
unique in that it is investigator initiated, and enjoys support of the Dutch Society of 
Hepatology. The VIRID study will be the first large study to definitely determine 
the role of high-dose weight-based ribavirin for treatment naive genotype 1 and 4 
patients. Additional information can be found at: www.virid.nl. 
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Ribavirin is an important component of the combination treatment 
against chronic hepatitis C virus (HCV) There appears to be a correlation 
between a higher ribavirin plasma concentration and an achievement 
of higher sustained viral response The hypothesis is that a higher ribavirin 
dose (25 29 mg/kg/day) compared to standard weight-based ribavirin 
will lead to higher plasma concentrations 
The aim of this study was to evaluate whether a higher ribavirin dose 
leads to elevated steady state plasma ribavirin concentrations in the 
first 12 weeks of treatment 
We are currently performing a randomized controlled clinical trial in HCV 
genotype 1 and 4 patients, with high viral load (>400,000 IU/ml) who 
receive pegylated interferon in combination with a standard ribavirin 
dose (12-15 mg/kg/day) compared to a higher ribavirin dose (25-29 mg/ 
kg/day) We studied plasma ribavirin concentrations at week 1,2,4,8, 
12, as determined by a validated high-performance liquid chromatography 
(HPLC) assay 
In this ana /̂sis a total of 95 samples from 19 included patients (12M, ZF), 
mean age 46 (range 18-61) years were analyzed The mean ribavirin 
dose at baseline was 26 2 mg/kg/day in the high ribavirin group vs 
13 4 mg/kg/day in the standard ribavirin group (p <0 05) Ribavirin 
plasma concentrations significantly increase over time (p=0 003) The 
concentrations at steady-state were significantly higher in the high dose 
ribavirin group (3 13 mg/L vs 1 73 mg/L, p=0 011) 
In the treatment of HCV genotype 1 &4 patients, treatment regimens 
with higher ribavirin dose leads to higher plasma nbavinn concentrations 
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Background 
The standard combination of therapy with peginterferon and ribavirin given for 48 
weeks results in a sustained viral response (SVR) of about 41-52%1'2. Ribavirin as an 
oral antiviral drug is central to HCV therapy. Current guidelines recommend weight-
based ribavirin dosing (usually between 800-1,400 mg/day) tailored according to 
genotype3·4. 
A number of studies have demonstrated a correlation between higher ribavirin plasma 
concentrations and SVR510. The mode of action of ribavirin remains to be elucidated 
and data regarding an optimal ribavirin dose and resulting "therapeutic" plasma 
concentrations are scarce. Two studies have demonstrated that ribavirin concentra-
tions are poorly correlated to the ribavirin dose adjusted for body weight1011. In 
addition, body weight, gender, age and Creatinin clearance have been identified as 
covariates influencing ribavirin concentrations. However, these variables only explain 
approximately 30% of the interindividual variability of ribavirin clearance1012. 
A gradually single dose escalation study determined that the bioavailability of 
ribavirin declines with increasing doses13. This study hypothesized that the absorp-
tion of ribavirin in the intestines is dose-dependent and saturable. The question 
whether a chronic high dosed ribavirin leads to non-proportionally elevated plasma 
concentrations was not addressed in this observational study. 
We set out to perform a randomized controlled clinical trial for chronic HCV 
patients with genotype 1 or 4 and high baseline viral load to compare currently 
accepted daily ribavirin dosage of 12-15 mg/kg with that of 25-29 mg/kg, both in 
combination with peginterferon alfa-2a14. The primary outcome measure of this 
study is SVR. We capitalized on this unique trial and set out to investigating the 
pharmacokinetic profile of high ribavirin dosing. 
Methods 
r - J ' I -.' I [ rìì-r '-
This study is part of a randomized controlled clinical trial that runs in the Netherlands 
from June 2008 until 201214. After written informed consent, patients receive 
peginterferon (alfa-2a) subcutaneously, once weekly, in combination with oral 
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standard weight-based (12-15 mg/kg/day) or a higher dose of ribavirin (25-29 mg/ 
kg/day) two times daily (supplement Table 1). Routine monitoring during hospital 
visits include assessment of viral load at week 0, 1, 2, 4, 8, 12, complete blood 
count, clinical chemistry, renal function, adverse events monitoring and body 
weight assessment. In patients with a hemoglobin (Hb) level of < 11.2 g/dL, epoetin 
beta is administered in a dose of 30,000 IU/ml/week. Epoetin beta has to be dis-
continued in case a level of Hb >12.4 g/dL is reached. 
This study was approved by the independent Medical Ethics Committee of the 
Radboud University Nijmegen Medical Center and Erasmus Medical Center, 
Rotterdam, and registered at www.clinicaltrials.gov (NCT00662220). 
At all scheduled hospital visits (1, 2, 4, 8 and 12 weeks after start of treatment), 
blood samples are collected for plasma ribavirin measurements. (Figure 1) Samples 
are collected in a heparinized vacutainer tube and stored at -40 °C until assay. 
Plasma concentrations of ribavirin were analyzed by a procedure used by D'Àvolio 
et al.15 with slight modifications. In brief, to 125 μ ι of plasma 1.5 mL acetonitril 
was added. The sample was mixed on a vortex mixer for 1 minute, followed by 
centrifugation at 11,000 rpm for 5 minutes. Afterwards, the organic phase was 
evaporated at 37 °C under a gentle stream of nitrogen gas, and reconstituted in 
125 μ ι of mobile phase (20 mM phosphate buffer pH 3.23). Twenty five μ ι of the 
resulting solution was run on a 4.6*150 mm Atlantis® T3 5 μιτι reversed phase C18 
column (autosampler columnoven 35 °C, flow rate 1.0 mL/min) and ribavirin was 
detected by use of a UV detector (λ 235 nm). 
Frequency tables are provided for baseline characteristics. Ribavirin plasma 
concentrations are expressed as mean with standard deviation (SD). Patient 
demographics were compared between patients with high and standard dose 
using Mann-Whitney U test or Fisher exact test where appropriate. The Wilcoxon 
signed-rank test was used to compare ribavirin concentrations between groups 
at different time points. Correlations between plasma ribavirin concentration, 
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Figure 1 . Flowchart study 
Weeks, ribavirin piasma 
measurement 
12 
ribavirin dosage (mg/kg), hemoglobin decrease (mmol/l) and ribavirin steady state 
were calculated according to the Spearman's rho test. Ribavirin concentrations 
were analyzed over time using repeated measurements ANOVA and Interpreted 
using the Greenhouse-Geisser method. 
All p-values were two-tailed and differences were considered significant when the 
ρ value was less than 0.05. All statistical analyses were performed using SPSS for 
Windows, version 14.0 (SPSS, Chicago, IL). 
Results 
Patient characteristics 
A total of 95 plasma samples from 19 patients were collected. A total of 12 men 
and 7 women with a mean age of 46 (range 18-61) participated in this pilot study. 
Ten patients were randomized in the standard and 9 patients in the high dose 
ribavirin group. The patient baseline characteristics are depicted in Table 1. 
Baseline log serum HCV was significantly higher in the group randomized to high 
dose ribavirin compared to standard dose. Mean ribavirin dose was 26.2 mg/kg/ 
day (SD 0.9) in the high dose ribavirin group vs. 13.4 mg/kg/day (SD 1.3) in the 
standard group (p <0.05). 
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Table 1. Baseline characlonslir s ot 19 genotype 1 and Ί HCV patients 
Patient characteristics 
Age - years 




Serum Creatinin clearance (ml/mm) 
Serum hemoglobin (mmol/l) 
ALT§(IU/ml) 
Serum HCV RNA Log,,, lU/mlJ (SD¥) 
Fibrosis score (METAVIR) > F3 
Genotype 1/4 π (%) 
Dosage ribavirin mg/kg (SO) 
A 
High ribavirin dosage 
n=10 
44 4 +14 5 
6(60) 
8(80) 
25 8 ± 4 9 
75 6 ± 14 2 
121 8 ± 20 0 
IS 5 ± 1 2 
64 ±27 
6 32 + 8 5 7 
3(30) 
10(100) 
26 2 + 0 9 
Β 
Standard ribavirin dosage 
n=9 
47 2 ±7 7 
6(67) 
8(89) 
26 4 ± 3.7 
82 2 ± 18 1 
130 7 ± 20 5 
14 7 + 1 3 
72 + 32 
1 77 ± 1 34 
3(33) 
8(89) 














tBody mass index, §alanin aminotransferase, thepatitis C virus ribonucleic acid and international units per 
milliliter, ¥SD standard deviation 
Figure 2 shows the mean plasma ribavirin concentrations for both ribavirin dose 
regimes within the first 12 weeks of therapy. Plasma ribavirin concentrations 
significantly increase in both groups overtime (p=0.003). Ribavirin concentrations 
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in the high ribavirin dose group began to asymptote by week 8 (2.97 mg/L) of 
therapy and these levels significantly differed from concentrations at week 1, 2 and 
4 (p <0.05). The concentrations at week 8 and 12 were significantly higher in the 
high dose ribavirin group vs. the standard dose group (3.13 mg/L vs. 1.73 mg/L, 
p=0.011). Intra- and interindividual variability of ribavirin concentrations of 
standard ribavirin dose at week 8 and later was 35% and 40%, respectively. For the 
high ribavirin dose group the intra- and interindividual variability was 29% and 30% 
respectively. 
Ribavirin steady-state concentrations in the high ribavirin dose regimen significantly 
correlated with ribavirin dosage mg/kg (r=0.906, p<0.01). For the standard ribavirin 
dose this correlation was not significant (r=0.183, p=0.637). (Figure 3) 
Io/et, 
Figure 4 shows the Hb decrease during the treatment for both groups. The overall 
Hb decrease compared between both ribavirin dose regimes over time was not 
different (p=0.374). There were 6 patients in the high ribavirin dose regimen, who 
had a Hb drop below 11.2 g/dL compared to 1 patient in the standard ribavirin 
group. These 7 patients were treated with Epoetin beta and none required a blood 
transfusion. 
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Figure 3. Correlation between ribavirin dose (mg/ky) and ribavirin steady-state for both ribavirin dose regimens 
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Discussion 
We demonstrate that higher ribavirin dose m combination with pegylated interferon 
a-2a leads to a less than proportional increase of ribavirin plasma concentrations 
than could be predicted on the basis is the individual dose regimen Higher ribavirin 
dose (mean 26 19 ± 0 92 mg/kg) showed a 1 6 fold higher ribavirin steady-state 
These results suggest that the absorption of ribavirin after administering higher 
dosages is partly saturable This partly contradicts published data, because in one 
single dose study it was claimed that AUC is linearly related to dose, although the 
Cmax displayed signs of saturabihty16 Data from higher doses of ribavirin shows 
also that the bioavailability declines with increasing doses of ribavirin13 A probable 
mechanism shows also the saturation of the Nl-purme transporting protein, which 
transports ribavirin across the cell membrane in the intestine17 
Despite the apparent saturation of absorption at higher ribavirin doses, there was 
still a considerable (~56 %) increase m ribavirin plasma exposure associated with 
the use of a higher ribavirin dose This is important because limited variation m 
plasma concentrations between study groups curtails the chance that there will be 
significant differences in the primary outcome 
Furthermore, in contrast to our expectations, there was not an excess of anemia in 
the high ribavirin group This might be due to the use of epoetin beta which was 
administered once Hb dropped below 11 2 g/dL 
In the literature, the optimal target ribavirin plasma concentration to reach the 
highest SVR rates has not been established yet A pharmacokinetic study found 
that the probability of response to treatment increases with higher plasma ribavirin 
concentrations There was a dose response curve and a target concentration of 
3 0-3 5 mg/L was associated with a SVR of 43% while concentrations > 4 0 mg/L 
led to even higher SVR rates (62%)10 One small prospective pilot study studied the 
association between higher ribavirin dosing and plasma concentrations18 The mean 
plasma ribavirin concentrations were 2 03 mg/L m week 4 and 3 5 mg/L at week 12 
and 24 In this study patients received ribavirin up to 2,540 mg/day (range 1,600-
3,600 mg/day) Nine out of 10 (90%) patients achieved SVR Because of the onset 
of anemia all patients were treated with concomitant erythropoietin18 Recently, a 
retrospective study demonstrated that ribavirin plasma trough concentration of 
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<2.5 mg/L at week 4 is a negative independent predictor for relapse after chronic 
hepatitis C virus (HCV) treatment19. Our pilot shows that a majority (89%) in the 
standard regimen group did not reach the threshold of > 2.5 mg/L at week 4, while 
a majority (80%) in the high ribavirin group did. 
The strength of our study is that plasma ribavirin concentrations were assessed as part 
of a prospective randomized controlled clinical trial that compared high with standard 
regimen. Because of the use of epoetin beta, ribavirin dosage could remain constant. 
The limitation of this study is that we did not include SVR as a relevant outcome 
and that the sample size is relatively small. Indeed, as such, the data can be 
considered to be preliminary, which aligns with the primary goal, to investigate 
the pharmacokinetic profile of ribavirin. 
We hope that in the future, this large randomized controlled clinical trial will aid in 
clarification of the role of a higher ribavirin dose and if this is related to a better 
viral outcome. 
In conclusion, this pilot study shows that in the treatment of HCV genotype 1 and 
4, treatment regimens with higher ribavirin dose leads to higher plasma ribavirin 
concentrations. 
Supplement table 1. Ribavirin dosage according to weight 
WÊÊÊmÊÊÊÊÊÊÊmÊÊÊÊmÊÊÊÊÊÊiamÊÊÊÊmmmÊÊÊÊÊÊÊÊÊÊmm 
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General Discussion 
and Future Perspectives 
Chapter 5 
This thesis describes studies that cover different aspects of chronic HCV infection 
and treatment. The studies vary from an epidemiological study, meta-analyses 
for HCV treatment optimization, to pharmacokinetic studies of ribavirin plasma 
concentrations in treatment of HCV. 
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The estimated prevalence of HCV was 0.2% among the general population residing 
in the eastern part of the Netherlands. Most physicians treat patients with HCV in 
clinical practice according to the recently issued Dutch HCV guideline. However, al­
most half of the physicians treat HCV genotype 1 and 3 patients with a rapid viral 
response at week 4 (RVR) longer than currently needed. 
The results of our cross-sectional study to assess the epidemiology of HCV infection 
and our survey among Dutch physicians are described in chapter 2. The prevalence 
of HCV infection (0.2%) derived from this study is slightly higher compared to 
healthy blood donors from the Netherlands. In 2001 approximately 0.0169% of new 
blood donors tested positive for HCV antibodies1. It is important to realize that blood 
donors are a self selected group of individuals that have lower rates of blood-borne 
infections compared to the general population. 
The actual prevalence in the general population is higher and estimated to be 
0.1-0.4%, but this is based on limited data and therefore it is uncertain how large 
the HCV problem is in the Netherlands. 
In 1995, a large Dutch study collected sera of 7,373 volunteers and found that only 
six tested anti-HCV positive (0.08%)2·3. This study shows a lower prevalence of HCV 
infection in general population than our study, probably due to underrepresentation 
of immigrants without Dutch nationality. 
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The prevalence we found is much lower compared to other countries. In the USA, 
the prevalence of HCV infection is estimated at 1.6%4·5. Various studies performed 
throughout Europe on the prevalence of HCV in the general population indicate 
prevalences ranging from 0.63% in Germany, 0.9% in Belgium to 1.2% in France6 8. In 
Southern Europe the prevalence varies from 1.6% in Spain to 4.8 to 26.0% in Italy910. 
The large variation is most probably due to differences in year of sampling and in 
the quality of the healthcare system and sterilization procedures. 
We conducted a survey among Dutch physicians, who were actively treating HCV. 
This shows that physicians treat patients with HCV in clinical practice according to 
the recently issued HCV guideline. The majority (65%) of respondents treat HCV 
patients during in a regular outpatient clinic, while 35% treat patients in a separate 
setting dedicated to the care of HCV patients. In literature, it is known that 
treatment with special hepatitis nurses in a dedicated outpatient clinic gives a 
significant improvement in patient follow-up and intention to treat, with a 
doubling in treatment rates11. 
We noticed that almost half of the physicians treat HCV genotype 1 and 3 patients 
with RVR longer than currently needed. According to recent guidelines patients 
with genotype 1, low viral load and RVR can stop after 24 weeks of treatment. In 
patients with genotype 3, low viral load and neither fibrosis nor RVR, treatment 
can be shortened to 12-16 weeks1213. In terms of financial aspects, occurrence of 
severe side effects and convenience for patients, shorter treatment duration with 
retained efficacy is desirable. 
Some 13% of the physicians use higher ribavirin dosages than currently advised. 
Some studies show that a higher starting dose of ribavirin is associated with a lower 
relapse rate and higher rate of SVR1416. A high dose of ribavirin is also associated 
with more frequent and serious side effects. For example anemia, which may require 
erythropoietin in many cases14'16. These are definitely areas for future improvement 
of the current standards of care. 
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VWiHt is Ihe oplirnal length of treatment in patients wth ncnot\po 2 and 3 ; 
Is higher ribrjvirm dosage more eifeolive in combination therap, toi patients sith HC. '' 
\Ne have assessed these objectives in two meta-analyses. The first meta-analysis 
shows that in HCV genotype 2 and 3 patients who obtain a RVR at week 4 a shorter 
treatment duration does not lead to different efficacy compared to standard 
treatment. The results of the second meta-analysis of HCV treatment indicates that 
higher weight- based dose of ribavirin is more effective in genotype 1 and 4 in 
achieving SVR than standard or fixed dose of ribavirin. 
The results of our meta-analysis of 7 randomized clinical trials (RCTs) shows that in 
HCV genotype 2 or 3 patients who obtain a rapid virological response at 4 weeks 
(RVR,) SVR rates after both treatment durations (12-16 weeks vs. 24 weeks) are not 
different. 
We created two separate forest plots, because included studies randomized either 
at baseline or at RVR. When patients were randomized at baseline the results favor 
standard therapy. These results are likely due to the proportion of patients that 
fails to achieve RVR at 4 weeks of therapy and has a higher tendency to relapse after 
the end of shorter therapy. 
The results we found were in line with the meta-analysis by Andriulli et al.17. However, 
in that study a mix of studies was compared with different study designs; including 
RCTs, an open-label historical-control study and results from a retrospective study. 
They also did not differentiate between randomization at baseline or at RVR. In 
our forest plot of studies where patients were randomized at RVR, we show that 
treatment durations (short or standard) were not different in terms of SVR outcome. 
Furthermore, apart from RVR, other (non) virological factors such as baseline 
characteristics, (e.g. ethnicity, gender) and liver histology may also contribute to 
the therapeutic success of shorter therapy. Racial factors influence the virological 
response even when standard treatment is given1819. In a study that pooled 
data of 2 clinical trials, severe fibrosis was a predictive factor for experience of 
both lower RVR and SVR rates and more frequent relapse after 12 or 14 weeks of 
antiviral therapy20. 
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Unfortunately, we could not perform a multivariate analysis to determine whether 
fibrosis stage influenced SVR in this meta-analysis, because different classification 
systems were used to stage fibrosis (e.g. METAVIR, Ishak-score, APRI-score). 
In our meta-analysis, we found that RCTs with weight-based dosages (800-1,400 
mg daily)2126 achieved higher SVR rates compared to fixed dose regimens (800 mg 
daily)27,28. This suggests that there might be a benefit of higher ribavirin exposure. 
It contributes to higher SVR rates and lower relapse rates in shortened treatment 
regimes in patients. 
Finally, our analysis provides important information for clinicians treating these 
HCV genotype 2 or 3 patients and suggests that RVR is an important parameter in 
determining success of shorter therapy. This is underlined by the results of a large 
RCT by Mangia et al. that also concluded that a shorter course of therapy (12 
weeks) is as effective as a 24 weeks course for patients with HCV genotype 2 or 3 
who have a response to treatment at RVR29. 
Abbreviated regimes are less expensive and reduce exposure to side effects and 
might have tolerability advantages over a 24-week regimen. 
The second meta-analysis focused on the question whether a higher ribavirin 
dosage is more effective than regular weight-based and fixed ribavirin doses in HCV 
combination therapy. The results of the meta-analysis of 8 RCTs shows that that 
weight-based dose ribavirin is more effective in genotype 1 and 4 in achieving SVR 
than fixed dose ribavirin (38% vs. 31%; RR 0.91 (95% CI 0.87 - 0.96, p=0.0001). For 
genotype 2 and 3 patients fixed ribavirin (800mg/day) is in favor. Reductions to 400 
mg/day in these HCV patients appears to be possible, as one RCT documented dose re-
ductions of RBV (up to 400 mg/day) which did not compromise treatment efficacy30. 
Furthermore, it shows that higher dosage of ribavirin in difficult-to-treat genotype 
1 and 4 patients, achieves non-significantly higher SVR rates (47% vs. 27%; RR of 0.80 
(95% CI 0.63 - 1.01, p=0.06). 
Higher response rates are achieved in the majority of patients that is able to toler-
ate/adhere to ribavirin dosing, indicating the importance of cumulative ribavirin 
exposure31. In addition to enhancing the virological response, ribavirin also helps 
to maintain the response and prevent relapse3235. 
123 
Crapte r 5 
Some studies suggest that higher ribavirin doses up to 15.2 mg/kg/day further 
increase SVR rates and significantly lower relapse rate36·37. Erythropoietin was 
used in this study to manage ribavirin induced anemia, which allowed patients to 
maintain on full ribavirin dose. Another study demonstrated that dosing ribavirin 
at double dose (mean 2,540 mg/day, range 1,600-3,600 mg) resulted in a 90% SVR in 
a cohort of 10 HCV genotype 1 patients. All patients suffered from severe anemia, 
which was managed with concomitant erythropoietin and blood transfusion38. 
These pilot studies which used higher doses of ribavirin prompted the development 
of two large trials termed the PROGRESS and the VIRID study. They will attempt to 
confirm the hypothesis that treatment with higher doses of ribavirin (1,400-1,600 
ribavirin mg/day in PROGRESS and 1,000-3,000 ribavirin mg/day in the VIRID study) 
is more beneficial in naive genotype 1 and 4 patients39·40. 
In conclusion, physicians should make important considerations when prescribing 
ribavirin. This includes selecting the appropriate starting dose and maintaining this 
dose by careful clinical management of any ribavirin-related side effects. It is crucial 
to optimize ribavirin dosage in order to achieve higher SVR rates and to minimize 
relapses. 
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In the first study we show that ribavirin steady-state concentrations can be predicted 
by early measurement of ribavirin concentrations in week 2 and week 4. In the second 
study we demonstrate that a higher ribavirin dose in combination therapy leads to 
significantly higher plasma ribavirin concentrations, with an increase that is less 
proportional to the increase in dose. 
The observational cohort study shows that early measurement of ribavirin at week 
2 and 4 can predict ribavirin steady-state concentrations. Furthermore, it shows 
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that steady-state concentrations of ribavirin are reached 8 weeks after start of HCV 
combination therapy. Ribavirin concentrations in this cohort are widely variable 
between different individuals, but with low intra-patient variation. 
In the literature, various studies show an association between ribavirin concentration 
and SVR4146. A recent review proposed an optimal therapeutic range of 2.0-2.5 mg/L 
at week 4 of HCV therapy to maximize the achievement of SVR47. This is confirmed 
by another study that shows that ribavirin plasma trough concentration <2.5 mg/L 
at week 4 is a negative independent predictor for relapse after the end of HCV 
treatment48. 
However, 75% of patients from our cohort did not reach a ribavirin concentration 
of 2.5 mg/L at week 4. This suggest that with the current standard weight-
based ribavirin dosing regimen, insufficient ribavirin concentrations are reached. 
A possible clinical implication is that adaption of ribavirin dose early during treatment 
potentially can lead to higher ribavirin steady-state plasma concentrations. 
There is currently no consensus on monitoring ribavirin plasma concentrations 
during antiviral treatment. Possibly, future studies can elucidate whether ribavirin 
dose adaption early during treatment based on monitoring of plasma concentrations 
will lead to higher steady-state concentrations and higher SVR rates. 
Finally, preliminary results of ribavirin plasma concentrations in the VIRID study 
(of which the design is also described in chapter 4) are described. It shows an 
increase in ribavirin steady-state plasma concentrations (2.97 vs. 1.89 mg/L) after 
administering a higher dose of ribavirin (mean 26.19 ± 0.92 mg/kg) compared to 
standard ribavirin dose in combination therapy for HCV. Our results suggest that 
twice daily may be saturable, but not at the dosages used in clinical practice, since 
an increase in dose resulted in increased plasma concentrations, with an increase 
not proportional to the increase in dose. Lindahl et al. also shows that the bio-
availability declines with increasing doses of ribavirin and suggest that absorption 
of ribavirin is saturable49. A probable mechanism is saturation of the Nl-purine 
transporting protein, which transport ribavirin across the cell membrane in the 
intestine50. 
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In a pilot study mean plasma ribavirin concentrations reached 2.03 mg/L in week 4 
to 3.5 mg/L at week 12 and 24 after gradually increased dose up to 2,540 mg/day 
(range 1,600-3,600 mg/day)38. 
As mentioned above a recent study demonstrated that ribavirin plasma trough 
concentration of <2.5 mg/L at week 4 is a negative independent predictor for 
relapse after chronic hepatitis C virus (HCV) treatment48. Our pilot shows that a 
majority (89%) in the standard regimen group did not reach the threshold of > 2.5 
mg/L at week 4, while a majority (80%) in the high ribavirin group did. 
In conclusion, some studies demonstrated a correlation between higher ribavirin 
plasma concentrations and early virologie response (EVR) and even SVR4146. These 
data suggest that ribavirin is important for the success of the combination therapy 
and it appears likely that higher ribavirin dosage (or more precise: exposure) is 
associated with higher cure rate. 
We hope that in the future our large randomized controlled clinical trial will 
elucidate the role of higher ribavirin dose and higher plasma concentrations for 
improved viral outcome. 
Conclusion and future perspectives 
Treatment of HCV has improved steadily during the last decade. With the current 
standard of care, improvement of SVR rates is considered to be the greatest 
challenge nowadays. In the future some strategies followed in order to improve 
SVR rates: 1) optimization of antiviral treatment duration; 2) adjustment of ribavirin 
doses; and 3) addition of new antiviral agents to the current treatment. 
Furthermore, selection of patients who benefit most of therapy and close monitoring 
of hepatitis C treatment are crucial components of hepatitis C therapy. Given the 
intensive treatment schedule with many side effects, long treatment duration and 
high costs of therapy, it is important that physicians have excellent knowledge and 
follow evidence based guidelines in order to improve patient outcome and provide 
the best care possible. 
Therefore, we think that it is crucial to refer HCV patients to dedicated hepatitis 
outpatient clinics with specialized hepatitis nurses. 
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Treatment outcome of HCV depends on various host and viral factors which are not 
variable. What we can influence is the dose of ribavirin, by finding an optimal higher 
dose to obtain higher SVR rates. Hopefully in the future, the VIRID study will add 
clarification on this topic. Measurement of plasma ribavirin concentrations in order 
to adjust the dose of ribavirin and thereby optimizing the SVR rates, is optional and 
should be investigated in the near future. 
In order to translate the currently available data to HCV treatment we present a 
flowchart (figure 1). This depicts a guideline which can be used by physicians who 
have a patient with chronic HCV infection. Ribavirin levels are not yet incorporated 
in this chart since more research in this field is required before incorporating levels 
in guidelines. 
Figure 1 . Flow chart of HCV palienls work-up and treatment (adapted from Do Bruijnc et al ) 
HCV serology and HCV RNA positive patient (pnmarv care) 
I Referral 
Hepatitis outpatient clinic Chopter 2 
(secondary/tertiary center) 
I 
Initial work up HCV 
(e g risk factors, HCV status, ultrasound, hverbiopsy) 
I 
Instruction of treatment by dedicated hepatitis nurse 
1 
Antiviral treatment according to genotype and subcategories of HCV patient 
Genotype 1 or A Genotype 2 or 3 ChoptCf 3 
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I I 
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„higher weight based ribavirin 
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Summary 
This thesis describes studies on different aspects of chronic Hepatitis C virus (HCV) 
infection and treatment Chronic HCV infection is often asymptomatic and causes 
chronic hepatic inflammation which may lead to liver fibrosis or cirrhosis and which 
can result in a broad spectrum of disease outcomes 
Different aspects were studied in this thesis 
1) How frequent is chronic HCV infection in the Netherlands? 
2) How and where do we treat chronic HCV infection? 
3) Can we optimize HCV treatment? 
A general introduction of chronic HCV infection, the epidemiology, treatment and 
the role of ribavirin in current and future treatment is given in chapter 1 
Chapter 2, describes the actual prevalence of chronic HCV infection in the Dutch 
population The prevalence we estimated was 0 2% among the general population 
residing in the eastern part of the Netherlands 
Furthermore in this chapter, we studied where and how Dutch physicians treat 
chronic HCV patients The majority (65%) of respondents treat HCV patients in a 
regular outpatient clinic, while 35% treat patients in a separate setting dedicated to 
the care of HCV patients 
The survey also shows that physicians treat patients with HCV m clinical practice 
according to the recently issued HCV guideline However, we noticed that almost half 
of the physicians treat chronic HCV genotype 1 and 3 patients with rapid viral re-
sponse at week 4 (RVR) longer than currently needed In terms of dosing of ribavirin, 
some 13% of the physicians use higher ribavirin dosages than currently advised 
In chapter 3 we describe two meta-analyses which 1) determine the optimal length 
of HCV treatment, and 2) to determine the optimal ribavirin dose m antiviral therapy 
In the first meta-analysis, we pooled 7 randomized trials to determine the optimal 
length of treatment in patients with HCV genotype 2 and 3 This shows that in 
HCV genotype 2 and 3 patients who obtain RVR at week 4 a shorter treatment is 
not different m terms of efficacy compared to standard treatment 
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In the second meta-analysis of 8 randomized trials, we conclude that a higher 
ribavirin dose in genotype 1 and 4 is more effective than a fixed ribavirin dose in 
HCV combination therapy m order to obtain sustained viral response (SVR) 
Chapter 4 includes 2 studies that describe plasma ribavirin concentrations in HCV 
patients during antiviral treatment. There are controversial results m the literature 
on the association between ribavirin plasma concentrations and treatment outcome. 
For the first study, we studied a HCV cohort m daily clinical practice, the other 
study is based on the first included patients of a randomized controlled clinical trial 
(VIRID study) that is currently conducted in the Netherlands from June 2008 until 
2012 The design of the VIRID study is also described m chapter 4. 
We show m our observational cohort study that steady-state plasma concentrations 
of ribavirin are reached 8 weeks after start of HCV combination therapy. Ribavirin 
steady-state concentrations can be predicted by week 2 and week 4 ribavirin 
concentrations. Furthermore, our data shows that ribavirin concentrations are 
widely variable between different individuals, but with a low mtra-patient variation 
In the preliminary VIRID data we found that with a twice daily high ribavirin dose 
(25-29 mg/day) plasma ribavirin concentrations reach a less than proportional 
increase m concentrations over time, when compared to a standard ribavirin dose 
(12-15 mg/day). In the near future, this large randomized controlled clinical trial 
will add more clarification of the role of higher ribavirin dose, and higher plasma 
concentrations and m treatment outcome 




Dit proefschrift beschrijft een aantal studies over verschillende aspecten van 
chronische hepatitis C (HCV) infectie in patiënten en de behandeling van deze 
aandoening. 
Chronische HCV infectie is vaak asymptomatisch en veroorzaakt een chronische 
ontsteking van de lever. Dit kan leiden tot leverfibrose of -cirrose wat kan resulteren 
in een breed spectrum van complicaties. 
In dit proefschrift richten we ons op de volgende onderzoeksvragen: 
1) Hoe vaak komt chronische HCV infectie voor in Nederland? 
2) Hoe en waar behandelen we chronische HCV patiënten? 
3) Kunnen we de HCV behandeling optimaliseren? 
In hoofdstuk 1 wordt een algemene beschrijving van HCV gegeven. Hierin worden de 
epidemiologie, de behandeling, de rol van ribavirine in de huidige en toekomstige 
behandeling beschreven. 
Hoofdstuk 2 beschrijft de prevalentie van personen die besmet zijn met een HCV 
infectie in de Nederlandse bevolking. Wij vonden een prevalentie van 0,2% HCV 
geïnfecteerde personen in het oostelijk deel van Nederland. 
Verder hebben we in dit hoofdstuk middels vragenlijsten onderzoek onderzocht 
waar en hoe Nederlandse artsen chronische HCV patiënten behandelen. De meer-
derheid (65%) van de respondenten behandelt HCV patiënten tijdens de reguliere 
polikliniek, terwijl 35% hiervan de patiënten behandelt in een aparte hepatitis 
polikliniek. Ons vragenlijsten onderzoek toont verder aan dat de meeste artsen 
HCV patiënten behandelen volgens de huidige richtlijnen. We zien echter dat bijna 
de helft van de artsen, HCV genotype 1 en 3 patiënten met een snelle virale response 
op week 4 (RVR), langer behandelt dan nodig is. Daarnaast, geeft ongeveer 13% 
van de artsen hogere doseringen ribavirine dan gebruikelijk in de richtlijnen. 
Hoofdstuk 3 beschrijft twee meta-analyses, die 1) de optimale duur van HCV geno-
type 2 en 3 behandeling bepaalt en 2) de optimale dosis ribavirine in de antivirale 
therapie onderzoekt. 
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In de eerste meta-analyse hebben we 7 gerandomiseerde studies geïncludeerd die 
de optimale lengte van de behandeling bij patiënten met HCV genotype 2 en 3 hebben 
onderzocht. Deze meta-analyse toont aan dat het resultaat van een kortere behan-
deling (12-16 weken) niet verschillend is van de standaard behandeling (24 weken) 
bij HCV genotype 2 en 3 patiënten die een RVR hebben. 
In de tweede meta-analyse van 8 gerandomiseerde studies laten we zien dat een ho-
gere dosering ribavirine in genotype 1 en 4 effectiever is in het behalen van genezing 
(SVR) dan een gefixeerde dosis ribavirine in de antivirale HCV combinatie behandeling. 
In Hoofdstuk 4 worden 2 studies beschreven over plasma ribavirine spiegels in HCV 
patiënten tijdens antivirale behandeling 
Er zijn controversiële resultaten in de literatuur over het verband tussen plasma 
spiegels van ribavirine en behandeleffecten na antivirale behandeling. In de eerste 
cohort studie hebben we plasma spiegels in HCV patiënten tijdens behandeling in 
de dagelijkse klinische praktijk gemeten. De gegevens voor de tweede studie 
komen uit een gerandomiseerde, gecontroleerde klinische studie (VIRID studie) 
die in Nederland loopt van juni 2008 tot en met 2012. Het design van deze studie 
staat ook beschreven in hoofdstuk 4. 
De observationele cohort studie laat zien dat ribavirine een steady-state plasma 
spiegel na 8 weken HCV combinatietherapie bereikt. Verder kunnen ribavirine 
plasma spiegels in week 2 en week 4 de ribavirine steady-state spiegels al voor-
spellen. Bovendien, blijkt dat ribavirine spiegels sterk variëren tussen verschillende 
individuen, maar dat deze spiegels op verschillende tijdspunten in dezelfde patiënt 
niet veel verschillen. Verder onderzoek is nodig om na te gaan of aanpassing van de 
ribavirine dosis in de eerste weken van de antivirale therapie ook leidt tot hogere 
ribavirine steady-state spiegels en betere genezing. 
De pilot studie toont aan dat, hogere ribavirine spiegels worden bereikt met 
ribavirine tweemaal daags een hoge dosis ribavirine (25-29 mg/dag), in vergelijking 
tot standaard ribavirine dosis (12-15 mg/dag), maar de toename in spiegels was 
niet evenredig aan de verhoging van de dosis. 
Hopelijk zal in de toekomst, de VIRID studie meer verduidelijking geven van de rol van 
de hogere doses ribavirine en hogere plasmaconcentraties op het behandeleffect. 
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Combination of pegmterferon and ribavirin is the current therapy for 
chronic hepatitis C infection (HCV) Interstitial pneumonitis is a rare side-
effect of HCV therapy and is an important cause of dose reduction or 
discontinuation, impairing success of antiviral therapy 
We performed a review of the literature in order to present diagnostic 
modalities and possible treatments for pneumonitis and to offer guide-
lines 
We searched for cases where pneumonitis as a side-effect of HCV 
treatment was documented First we performed a literature search via 
PubMed and Web of Science interface and second we searched three 
drug toxicity databases We systematically analyzed all case reports 
with respect to clinical manifestations, type of treatment, and outcome 
A literature search revealed 19 articles, containing 25 case descriptions, 
while we traced 33 cases from the drug toxicity databases 
Pneumonitis presented with any of the combination of fever, dyspnea, 
and cough and can arise with any type of (conventional or pegylated) 
interferon Mortality secondary to pneumonitis was seen in 7% of cases, 
exclusively with pegmterferon a-2b In most cases therapy was discon-
tinued and steroids were started 
Interferon-induced pneumonitis during HCV treatment is a severe 
complication and should be recognized in order to prevent further 
pulmonary damage and/or death 
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Introduction 
Hepatitis C (HCV) persists in up to 85% of patients and may result in liver cirrhosis 
and hepatocellular carcinoma1. The combination of peginterferon and ribavirin is 
the mainstay of treatment. Eradication of the virus can be achieved m up to 90% of 
chronic HCV patients, depending on a number of host- and virus-related factors 1·2. 
Successful treatment results in resolution of hepatic necroinflammation and regression of 
fibrosis. Though potentially successful, peginterferon and ribavirin are known to cause 
various side-effects in HCV patients. Most individuals suffer from some side-effects 
such as flu-like symptoms, myalgia, fatigue, gastrointestinal disturbances, psychiatric 
disorders, and hematological abnormalities such as anemia and leukopenia35. 
These adverse effects are relatively common and can be managed with supportive 
care. There are also less well known side-effects of antiviral treatment that may 
hamper successful eradication of the virus. Knowledge of the extensive gamut of 
side-effects of combination therapy is critical for the adequate management of 
side-effects. Pulmonary toxicity in patients undergoing HCV combination treatment 
is rare, and may include interstitial pneumonitis, sarcoidosis, pleuritis, bronchiolitis 
obliterans organizing pneumonia (BOOP), and exacerbation of asthma6·7. Pneumonitis 
occurs only rarely as a side-effect of HCV combination therapy and can arise at any 
stage of the treatment. Most commonly it presents with cough, which is difficult to 
differentiate from the ubiquitous cough that may occurs as a common side-effect 
of combination treatment. 
Interferon is the agent that is thought to be associated with pneumonitis in these 
patients. This paper aims to review the salient issues of pneumonitis in the setting of 
HCV combination treatment and aims to offer guidelines for diagnosis and treatment 
of pneumonitis. 
L 1 ι- Ή f ΠΙ r 
A 51-year-old male was seen in August 2005 because of HCV infection. He had been 
using intravenous (i.v.) drugs until 1985 and his medical history revealed multiple total 
hip replacements and revisions because of hip necrosis attributed to i.v. drug-related 
blood-borne infections. Liver function tests were abnormal: alanine aminotransferase 
(ALAT) 237 IU/L (normal <45 IU/L), aspartate aminotransferase (ASAT) 235 IU/L 
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(normal < 50 IU/L), c-glutamyl transpeptidase 241IU/L (normal <55 IU/L), and bili­
rubin 19 μιτιοΙ/Ι. (normal <10 μηηοΙ/Ι.). The patient was infected with genotype 3 
HCV virus with high viral load ([>5 χ IO5 lU/ml). 
A liver biopsy was performed and showed moderate necroinflammation with 
portoportal fibrosis (METAVIR; grade A2, score F2). In view of this advanced stage 
we offered the patient a 24-week treatment for HCV consisting of peginterferon 
a-2b (Pegintron®; 150 μ§ s.c. weekly) in combination with ribavirin (Rebetol®; 400 
mg twice daily). 
Four weeks after starting treatment he consulted us for a dry cough. Chest X-ray at 
that time showed no abnormalities. Although dry, nonproductive cough is usually 
caused by ribavirin, it typically clears after stopping the drug. The dry cough, however, 
persisted after end of treatment, being the reason to consult a chest physician. 
Physical examination revealed bibasal crepitations. A new chest radiograph showed 
bilaterally a diffuse, interstitial pattern (Fig. la) and chest high-resolution computed 
tomography (HRCT) demonstrated bilateral ground-glass opacities in central 
and upper zones (Fig. lb). Pulmonary function tests indicated a restriction and 
a diminished diffusing capacity. 
Figure 1 . A. Chest X-ray with diffuse, bilateral interstitial pattern. B. High-resolution computer 
tomography image showing bilateral ground-glass opacities in central zone. 
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Maximal incremental cycle ergometry showed decreased breathing reserve (0 l/min), 
high breathing frequency (65/min), and exercise-induced hypoxemia caused by an 
oxygen uptake problem, compatible with interstitial pulmonary disease. Results 
from bronchoalveolar lavage supported a diagnosis of drug-induced interstitial 
pneumonitis (cell count 1.68 xl09/L, 73% lymphocytes, CD4/CD8 ratio 0.5). The 
results of cultures and stains of the bronchoalveolar lavage specimens were 
negative for bacteria, fungi, acid-fast bacteria, cytomegalovirus, herpes simplex 
virus, and malignant cells. There were no signs of infection (blood culture was 
negative). As after 6 weeks the cough persisted, steroids up to 40 mg daily 
were started, which resulted in slow amelioration of symptoms, normalization of 
pulmonary function tests, and disappearance of the ground-glass effect on HRCT. 
One year after end of treatment the patient is well, without evidence of recurrence 
of hepatitis C. 
Methods 
[ iterature 
First we performed a literature search for articles on pneumonitis as a side-effect 
of HCV treatment in order to obtain a comprehensive overview of this particular 
side-effect. We took advantage of the PubMed and Web of Science interface 
(http://www.ncbi.nlm.entrez and http://apps.isiknowledge. com) and searched 
with the following keywords: interferon, interstitial, pneumonitis, and hepatitis C, for 
the period 1990-2008. Articles written in English, French or German were included 
in the analysis. Furthermore, we searched the three drug toxicity databases. We 
included the Netherlands Pharmacovigilance Center (www.lareb.nl) database and 
the Drug-Induced Lung Diseases database (www.pneumotox.com), and lastly we 
performed an exhaustive search of the database of the World Health Organization 
(WHO) via the Uppsala monitoring center (http://www.who-umc.org). We used as 
keywords interferon and pneumonitis. The WHO database is a collection of data 
about adverse drug reactions from around the world, especially from countries 
that are members of the WHO, and the generation of signals of drugs which might 
possibly have problematic side-effects. 
Sjpplemerils 
Inclusion criteria were cases that developed interstitial pneumonitis in the setting 
of HCV treatment, written in English, French or German. Exclusion criteria were 
other pulmonary diseases, e.g., sarcoidosis, exacerbation of asthma, BOOP, acute 
respiratory distress syndrome (ARDS), infectious pneumonia, liver transplanted 
patients, HIV co-infected patients, and interferon beta treatment. 
Patients who developed interstitial pneumonitis during interferon therapy with 
a disease other then hepatitis C were also excluded. The references of the traced 
articles were scrutinized for additional articles. 
Initial analysis yielded a total of 291 articles. The abstracts of this set of articles 
were scrutinized for cases that developed (interstitial) pneumonitis in the setting 
of HCV treatment. Subsequently data were retrieved with special attention to the 
following items: demographics (ethnicity, gender, and age), dosage and type 
of (peg)interferon, concomitant use of ribavirin (dosage), symptoms, interstitial 
pneumonitis, onset, symptoms, and outcome on follow-up. 
Results 
Articles 
We retrieved 19 articles, which contained detailed clinical descriptions of 25 cases 
of interstitial pneumonitis during or after HCV treatment. Our own case was added 
to the analysis. Articles were published in the time frame 1988- 2008. 
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A total of 25 cases, 12 (48%) males and 13 (52%) females, with mean age of 55.2 
years, developed an interstitial pneumonitis. Ethnicity was mentioned in seven cases, 
being Caucasian (five) and Asian (two). Tables 1 and 2 present the demographic 
characteristics of all cases. Fourteen patients were treated with conventional 
interferon, while 11 patients developed pneumonitis during or after treatment 
with peginterferon and ribavirin. 
Table 1 Summary of case reports in literature of interstitial pneumonitis associated with the use of interferon without nbavrin lor the treatment of Hepatitis C 
Author(Reference) Gender Age Ethnicity TypeoflFN Dose 
(years) (|ig/ wk) 
Onset Symptoms Outcome 
Kamisako et al 
Chin et al 
Female 60 Japenese a-2a 
Female 58 a-2b 
3 M U ι m 11w 
9 M U ι m 11w 
8 weeks fever, severe dry cough resolved without treatment 
12 weeks dyspnea resolved without treatment 
Female 72 lymphoblastoid 6 MU q d χ 10 days then 20 days fever, dyspnea 
IFN 6 M U t i w 
steroid treatment, persistent 
symptoms 
Hizawa et al " 
Moriya et a l I 3 
























6 MU ι m q d χ 2 wk, 
then 11w 
3 MU ι m q d χ 2 wk, 
then 11 w 
10 MU ι m q d χ 2 wk 
then 11 w 
cumulative 272 MU 
cumulative 506 MU 
cumulative 700 MU 
e i O M U q d x 2 w k 
then 11 w χ 22 wk 
6 weeks dyspnea 
3 weeks fever, dyspnea 
6 weeks dry cough, dyspnea 
4 weeks exertional dyspnea 
16 weeks dry cough, slight fever 




resolved with steroids 
resloved wit steroids 
9 weeks dry cough, dyspnea resolved with steroids 
resolved with steroids 
resolved with steroids 
resolved with steroids 
all three resolved without treatment 
IFN interferon, / m intramuscular, MU million units, q d daily, 11 w thrice weekly, Φ Not specified 
Table 2. Summary ol case reports m literature of interstitial pneumonitis associated with the use of peqyiated interferon and ribavirin combination therapy for the 
tredlment ol Hepatitis C 
Author(Reference) Gender Age Ethnicity Type of Dose Ribavirin 




Furhmann et al Male 51 a-2b 1,200 Fever, dry cough, 
dyspnea 
death 
Abi-Nassifetal. Male 49 Caucasian a-2b Cough 
and dyspnea 
death 
Carnlo-Esper et al Female 43 a-2b 120 800 48 Dyspnea, cough, fever 
Hil l ieretal Female 68 Caucasian consensus 9 μg daily 1,000 
IFN 
8 Shortness of breath Discontinued and steroids 
Renou et al. Female 58 Caucasian a-2b 
a-2a 
150 1,000 12 Dyspnea 
180 Ι,ΟΟΟ+Α" 12 Dyspnea 
Discontinued and Resolved with 
inhalation steroids 
Kumar et al 
Midtur ie ta l . ' 
Chen et a l 2 0 
Son et a l 2 1 
Rocca et al " 
Slavenburg et al. 
Nemivant et al " 
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Cough, diarrhea, nausea 
Dry cough 
Φ 
Signs of pneumonia 
Dry cough 
Dyspnea, hypoxia 
dry cough and dyspnea 
Discontinued and Resolved 
with steroids 
Resolved after discontinuation 
Φ 
Resolved after discontinuation 
Φ 
End of treatment and resolved 
with steroids 
Discontinuation and resolved 
with steroids 
inhalation steroids 
PEG-IFN pegvlated interferon, ^'Amantadine, t Not specified 
Pneumonitis as d consequence ol (ppg)inter)eron ribavirin corribindUon Iherapy lor hepalili* G 
Interferon a-2b had been used in eight patients (62%), while interferon a-2a and 
lymphoblastoid interferon (6 million units (MU) daily χ 10 days, then 6 MU thrice 
weekly) was used in one single case. Interferon type was not specified in three cases. 
Dosages regimes varied with type of interferon and are presented in Table 2. Onset 
of symptoms of interstitial pneumonitis ranged from 20 days to 23 weeks of therapy. 
Symptoms included cough, dyspnea, and fever. 
CcTbiridi ,r ILcrao, Cast-
Peginterferon a-2b was used in eight patients (67%), while peginterferon a-2a was 
used in four patients (33%). Consensus interferon (Infergen, 9 μg q.d.) was given in 
a single case. Dosage regimes varied from 100 to 180 μg/week, depending on type of 
peginterferon, and from 400 to 1,200 mg/day for ribavirin. In two cases Amantadine 
was added to the treatment regimen. 
Onset of symptoms of interstitial pneumonitis ranged from 2 to 12 weeks of therapy. 
Iherap, fcr inVrstiiial Pneumonitis 
In all interferon cases therapy was discontinued, and five of these cases resolved 
without treatment8 1 0. Eight patients needed to be treated with various steroids. 
Interstitial pneumonitis in a 72-year-old female patient was treated with 30 mg/ 
day prednisolone, and she was then maintained on a regimen of intermittent pulse 
therapy with 100 mg/day; a 56-year-old male patient was started with 2 g/day 
methylprednisolone for 3 days and 40 mg/day prednisolone for 2 days10. Prednisolone 
(60 mg/day) and 100 mg/day azathioprine were given after a relapse of interstitial 
pneumonitis that was initially treated with 30 mg/day prednisolone 11. 
In one case of therapy with methylprednisolone pulse therapy, 1 g/day i.v. for 3 
days was given, followed by 40 mg/day oral prednisolone twice over 2 weeks; the 
other cases in that article received 50 mg/day oral prednisone12. Therapy for one 
case was not specified13. In eight cases combination therapy was discontinued and 
steroid therapy was initiated. While dosage and length of steroid treatment was 
highly variable, most authors started at a relatively high dosage. Intravenous therapy 
with 180 mg/day methylprednisolone was started in one case14, while other authors 
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started with 125 mg/day prednisolone1516. Others started patients on oral steroid 
therapy (40 mg) 6 · 1 7 · t h l s s t u d v , while two authors initiated inhalation steroids 18'19. 
Interstitial lung disease resolved in one case with oral antibiotics, given under 
presumptive diagnosis of community-acquired pneumonia. She recovered without 
sequel7. In four combination-therapy cases the dosage of steroid therapy was not 
defined2 0 2 3. 
Pnnurnonitis Cases from Drug Toxiuly Databases 
We identified 60 pneumonitis cases in association with (peg)interferon a from 
the WHO database. In 33 cases the indication of (peg)interferon (and ribavirin) 
combination treatment was HCV. There were 16 (48%) males and 15 (45%) females 
in this cohort, with mean age of 53 years. We failed to retrieve cases that met 
the inclusion criteria from the Netherlands Pharmacovigilance Center and Drug-
Induced Lung Diseases databases. Interferon monotherapy was used in three (9%) 
patients. 
Interferon a-2b in combination with ribavirin was used in eight patients (24%), 
while interferon a-2a in combination with ribavirin was used in a single case. 
Peginterferon a-2b in combination with ribavirin had been used in 6 patients (18%), 
while in 13 patients (39%) combination therapy with peginterferon a-2a was used. 
In two cases type of interferon and ribavirin was not described. 
Dosages regimes varied from 80 to 180 μg/week, depending on type of peginterferon, 
in combination with ribavirin (800-1,200 mg/day). Onset of symptoms of interstitial 
pneumonitis ranged from 23 days to 10 months of therapy. Four patients recovered 
and one patient died after drug-induced pneumonitis; outcomes of the remaining 
patients were not described. There was no description on treatment regimen for 
pneumonitis. 
f U\-ïn\\ 
Collectively, the cohort consisted of 25 patients from literature cohort and 33 patients 
from the drug toxicity database. Four patients (7%) from these two cohorts died 
following development of interstitial pneumonitis. All patients had been treated 
with peginterferon a-2b. Death in one case was due to multiple organ failure14, 
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in another case due to cerebral edema15, and in one case because of development 
of acute cholestatic hepatitis16. The cause of death of one case from the WHO 
database was not described. 
Discussion 
Interstitial pneumonitis occurs only rarely as a side-effect of HCV combination 
treatment and often leads to discontinuation of therapy, which has great implications 
for patients. In this article we presented our case of pneumonitis during combination 
therapy and performed a review in order to generate guidelines to manage symptoms 
and treatment. Given the paucity of reports with interstitial pneumonitis after riba­
virin monotherapy, we suspect that interferon is the culprit. 
The most common presenting symptom of pneumonitis is any combination of dry 
cough, dyspnea, fever, and fine inspiratory crackles noted on examination. Hemop­
tysis, wheezing, and signs of consolidation are rare. Onset of pneumonitis can be at 
any stage of HCV treatment, supporting the idiosyncratic nature of this side-effect. 
Chest radiographs usually show bilateral patchy infiltrates or opacifications, and 
thin-section CT scans show bilateral patchy consolidation as well as ground-glass 
attenuation24. 
In most cases, symptoms of pneumonitis are reversible after cessation of treatment 
with (peg)interferon and ribavirin, again in support of drug-induced interstitial 
pneumonitis. There is no consensus regarding treatment of interstitial pneumonitis 
induced by (peg)interferon and ribavirin. Upon review of the literature, three options 
are possible: first, to stop combination treatment of HCV and wait until the disease 
resolves, which was done in a limited number of cases710; second, to give steroids, 
although dosage and route of administration regimes vary widely6·1 0"1 8' t h i s s t u d v; and 
thirdly, in therapy-resistant or relapsing cases, adding azathioprine to steroids may 
be beneficial in order to resolve the interstitial pneumonitis11. 
The relatively high mortality rate in our series suggests that a more aggressive 
approach is warranted, and favors the early administration of steroids. One 
remarkable finding is that mortality occurred exclusively in patients with peginter-
feron-induced pneumonitis in comparison with conventional interferon (7% versus 
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0%). The reason for this is unclear, but (peg)interferon has been associated with 
other pulmonary toxicity such as sarcoidosis, pleuritis, BOOP, and exacerbation of 
asthma. Patients who died in the combination-therapy group were relatively young 
and had no relevant pulmonary or other severe diseases in their medical history. 
The doses of peginterferon and ribavirin varied but ranged within limits offered by 
treatment guidelines25. 
The mortality, only observed in patients treated with peginterferon and ribavirin 
combination therapy, raises the issue of whether the peg molecule increases 
the severity of pneumonitis once it arises. Interferon toxicity is generally dose and 
duration dependent26, which leads us to speculate that pulmonary toxicity may 
occur more severely with long-acting peginterferon; however, we saw no effect of 
dosage on the occurrence of pneumonitis. Patients died due to different causes 
(e.g., hypoxia-induced cerebral edema, acute cholestatic hepatitis, and multi-organ 
failure), all were induced by complications after initially interstitial pneumonitis. 
One alternative explanation for the increased mortality might be that all patients 
with peginterferon were also treated with ribavirin, although ribavirin per se is not 
associated with pulmonary toxicity. 
Our data suggest no significant difference between interferon a-2a or 2b, which 
suggest it is not due to the interferon molecule. In most interferon monotherapy 
cases of interstitial pneumonitis in HCV treatment in Japan the use of Sho-Saiko-to, 
a herbal medicine, led to pneumonitis. Sho-Saiko-to has been approved by the 
Japanese Ministry of Health and Welfare and has often been administered in chronic 
viral liver disease27. 
The mechanism of this side-effect, probably caused by interferon, remains unclear 
and several pathophysiological mechanisms have been proposed, centering on the 
known immunomodulatory activity of interferon28. Interferon has direct antiviral 
and immunomodulatory effect, including cytokine reduction, increased natural killer 
cell function, and enhanced cellular expression of major histocompatibility class 1 
antigens28-30. It is plausible that interferon triggers a lung-specific immune-mediated 
response resulting in interstitial pneumonitis, similar to other autoimmune diseases. 
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Conclusion 
Failure to recognize interferon-associated pulmonary toxicity may result in persis-
tence of pulmonary damage. Mortality was seen only in patients treated with 
pegylated interferon combination therapy. Therefore, clinicians should be aware 
of development of interstitial pneumonitis in chronic hepatitis C patients who develop 
pulmonary symptoms such as cough or dyspnea. The threshold for obtaining 
chest X-ray or pulmonary HRCT scan in these patients should be low. 
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In a recent issue. Van Leusen et al. described a series of seven haemodialysis patients 
with chronic hepatitis C (HCV) who were treated with peginterferon alfa-2a (Pegasys®) 
and ribavirin (Copegus®), which resulted in sustained virological response (SVR) in 
five patients (71.5%)1. Despite their encouraging results, we think that higher ribavirin 
dosages would further boost SVR. The authors report that their patient 1 did not 
respond to combination treatment of 135 μg peginterferon alfa-2a once a week 
and ribavirin 100-300 mg/day. We offered retreatment to this 39-year-old male. 
He was infected with HCV genotype l b and had a low viral load (100,000 Ill/ml). 
We started him on peginterferon alfa-2b (Pegintrone)150 μg and ribavirin (Rebetol®) 
400 mg/day. Within 2 weeks his plasma ribavirin levels reached 17.1 μg/ml.We 
therefore reduced ribavirin to 200 mg/day alternating with 400 mg/day. After 6 
weeks ribavirin levels were 6.5 μg/ml, and dosage was maintained. Darbepoetin 
alfa dosage was increased from 20 μgto 150 μg/week. Haemoglobin decreased to 
6.4 mmol/l at Week 12 and reached a nadir of 4.9 mmol/l after 28 weeks, but did not 
decrease further. Treatment was well tolerated and dose reduction or discontinuation 
due to adverse events was not needed. HCV RNA levels were undetectable after 8 
weeks and he reached SVR. He received a renal transplant 1 year later. HCV treatment 
in haemodialysis patients is crucial as these patients have a higher risk of developing 
cirrhosis and hepatocellular carcinoma. Timing of treatment is critical and needs to be 
performed prior to kidney transplantation as interferon can promote graft dysfunc­
tion2. Therefore, combination therapy should be considered in all HCV-infected 
ESRD patients. Ribavirin is an essential component of HCV combination treatment 
and increases the SVR rates from 37% to 60% compared to interferon monotherapy3. 
Toxicity, especially haemolytic anaemia, adds a layer of complexity. This led some 
authors to suggest that ribavirin is contraindicated in ESRD patients because of the 
risk of'life-threatening' haemolysis2. Our data and those of Van Leusen et al. suggest 
that ribavirin does not lead to uncontrollable haemolysis1. This corroborates with a 
recent study on 35 haemodialyzed HCV patients who were treated with peginterferon 
alpha-2a (135 μg weekly) and ribavirin 200 mg/day. A total of 26 patients developed 
severe anaemia and one patient uncontrolled anaemia (Hb 3.27 mmol/l) that led to 
treatment discontinuation, while the others required an increase of erythopoietin-
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alfa. This regimen was successful in 15 patients, while ribavirin was reduced to 200 mg 
every 2 days m 11 patients. SVR was reached m 97%4. From these data it appears 
that higher ribavirin plasma concentration increases the chance of viral clearance 
In the study of Van Leusen et al., ribavirin was kept at a relatively low level (1.5-2.5 
μg/ml)1 while m our (successfully treated) case we reached at considerably higher 
levels, as m the 11 patients that necessitated ribavirin dose reductions plasma 
concentrations were 5.7 ± 1.5 μg/ml4. These considerations led to a Dutch nation­
wide randomized controlled clinical trial that aims to compare the current standard 
therapy with a regimen that includes double dosage of ribavirin in naive HCV 
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Na de afronding van mijn coschappen en het behalen van mijn artsexamen ben ik 
op een bijzondere manier in contact gekomen met prof dr J Β M J Jansen HIJ bood 
me een baan aan bij de afdeling Maag-, Darm- en Leverziekten als arts-onderzoeker 
Daar kwam ik terecht m "De Kelder", het holst van de leeuw wat betreft onderzoek 
op de afdeling MDL De vier jaren die ik daar heb meegemaakt waren enorm leuk 
en leerzaam en dat is onder andere te danken aan vele mensen, die ik op deze 
manier ontzettend wil bedanken voor alle hulp 
Prof dr J PH Drenth, beste Joost, ik wil je graag bedanken voor je steun, begeleiding 
en vertrouwen tijdens dit promotietraject Je gedrevenheid en enthousiasme zijn erg 
aanstekelijk1 Je hebt me veel geleerd m de wereld van wetenschappelijk onderzoek 
en de belangen die daarbij een grote rol spelen Ik geef toe dat ik misschien met altijd 
even makkelijk was, want als ik ergens mijn zinnen op zet dan ben ik er moeilijk 
vanaf te brengen Ik heb de wekelijkse gesprekken met jou altijd als leerzaam ervaren 
en vond de congressen altijd erg gezellig 
Dr M G H van Oijen, beste Martijn, je was eerst zelf m "de Kelder" nog druk bezig met 
je eigen proefschrift en de afronding daarvan, maar ondertussen was je daar de 
grote spin m het web Jouw kennis was onmisbaar en mets of niemand was teveel 
voor jou De tissues stonden bij wijze al klaar en daar hebben veel mensen gebruik 
van gemaakt Alle frustraties, successen en weekendverhalen werden met jou 
gedeeld Ik wil je erg bedanken voor al je hulp tijdens mijn hele promotietraject en 
ben ervan overtuigd dat door jouw hulp dit proefschrift mede tot stand is gekomen 
Dr D M Burger, beste David, heel veel dank voor je begeleiding van het farmacolo­
gische gedeelte van mijn proefschrift Je stond altijd klaar om me te helpen en ik 
heb veel van onze bijeenkomsten geleerd 
Dd k vco d 
Dr R J de Knegt, beste Rob, dank voor de beoordeling van een aantal van mijn 
manuscripten Daarnaast heb ik de samenwerking met jou en het hele VIRID team 
(met o a Martin, Robert en Wanda) als zeer prettig en gezellig ervaren Ik ben zeer 
benieuwd naar de resultaten van het onderzoek 
Dr L A S van Kerkhoven, beste Lieke en paranimf, door jou ben ik aangestoken met 
het doen van onderzoek JIJ hebt me m het begin de kneepjes van het vak geleerd 
en ik kon gelukkig altijd bij je terechti Daarvoor wil ik je heel erg bedanken, want 
het viel met mee om vanuit de kliniek ineens onderzoek te doen Je bent daarnaast 
een goede vriendin en ik hoop nog vele jaren leuke uitjes met je hebben 
Dr L van Keimpema en Dr Κ F Kok, beste Loes en Karin, jullie zijn me voorgegaan 
Met zijn allen zijn we er druk mee bezig geweest en hebben we elkaar goed gesteund 
Ik heb genoten van alle gesprekken en Loes wat hebben we het leuk gehad tijdens 
alle congressen in zowel binnen- als buitenland succes met je verdere carriere 
Karin, succes met je tweede zwangerschap 
Beste Mieke, Merel, Melissa, Björn en Leo, leuk was het om met jullie te werken en 
de weekenden, liefdeslevens, huizenjachten, frustraties en successen van het 
onderzoek en de opleiding mee te maken Het is ontzettend belangrijk om een leuk 
team op je werk te hebben, omdat het doen van onderzoek en het schrijven van 
teksten soms best eenzaam voelt 
Manneke, je had samen met David en Ton de studie naar ribavirme plasma spiegels 
opgezet en voor een groot deel uitgevoerd1 Ik had het stokje van je overgenomen en 
ik wil je erg bedanken voor al je hulp die je hebt gegeven om het artikel te verbeteren 
en je hulp bij het voorbereiden van de presentaties 
Janneke, ex-huisgenoot van me Heel erg bedankt voor het lay-outen van het proef-
schrift en tips die je me hebt gegeven 
Bedankt Karin, Carilme en Sanne voor alle hulp tijdens de klinische studies en 
hepatitis poli Daarnaast ook dank aan alle patiënten die hebben deelgenomen aan 
de verschillende studies 
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Alle stafleden en arts-assistenten op de afdeling MDL, de klinische besprekingen 
vond ik altijd erg leuk en leerzaam, bedankt voor jullie interesse naar alle klinische 
studies en het leveren van patiënten daarvoor. Alle labmedewerkers en in het 
bijzonder Renee, bedankt voor jullie hulp en kennis. Helaas is het onderzoek naar 
SNP's in HCV patiënten niet verder meer uitgewerkt. De secretaresses van de MDL, 
het was gezellig met jullie, bedankt voor de leuke personeeluitjes die jullie altijd 
organiseren, en voor de vele statussen die jullie hebben moeten zoeken voor mijn 
database voor HCV patiënten. 
Collega Robert en studenten Ines en Ronne, bedankt voor jullie hulp met de 
meta-analyses, zonder jullie hulp had ik deze nooit kunnen uitvoeren. 
Lieve studiegenoten, Nanny, Maart, Kaat, Kim, Liek, El en Kaat, bedankt voor jullie 
interesse en gezelligheid tijdens vele kroegavonden. Vaak waren jullie degene die 
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Stellingen behorend bij het proefschrift 
Hepatitis C and Ribavirin; Focus on Ribavirin as an 
important Component in Hepatitis C Treatment 
Serena Slavenburg, 7 januari 2011 
1. De prevalentie van hepatitis C geïnfecteerde personen in het Oosten 
van Nederland is niet hoog. (dit proefschrift) 
2. Bijna de helft van de Nederlandse specialisten behandelt hepatitis C 
genotype 1 en 3 patiënten met een snelle virale respons op week 4 (RVR), 
langer dan nodig is. (dit proefschrift) 
3. Een kortere behandeling (12-16 weken) van hepatitis C genotype 2 en 3 
patiënten die een snelle virale respons hebben op week 4 (RVR), is even 
effectief als de standaard behandeling (24 weken), (dit proefschrift) 
4. Het gebruik van een hogere dosis ribavirine (op gewichtsbasis of hoger 
1200-1600 mg/dag) in hepatitis C genotype 1 en 4 patiënten, leidt tot 
meer genezing dan een gefixeerde dosis ribavirine (800 mg/dag) in de 
combinatie behandeling, (dit proefschrift) 
5. Ribavirine plasma spiegels in week 2 en 4 kunnen, tijdens de antivirale 
hepatitis C behandeling, de ribavirine steady-state plasma spiegels al 
voorspellen, (dit proefschrift) 
6. Verder onderzoek is nodig om na te gaan of aanpassing van de ribavirine 
dosering in de eerste weken van de antivirale therapie ook leidt tot 
hogere ribavirine steady-state spiegels en betere genezing. 
7. The man who is swimming against the stream knows the strength of it. 
(Woodrow Wilson) 
8. Those who walk into the sun leave the shadows behind them. 
9. Experience is a hard teacher because she gives the test first, the lesson 
afterwards. (Vernon Law) 
10. Het kunnen maken van keuzes in het leven, zou veel meer als een 
voorrecht beschouwd moeten worden. 
11. Indien tegenslag je sterker maakt, hoefje als promovendus nooit aan 
krachttraining te doen. 
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